pravastatin has been researched along with simvastatin in 765 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.39) | 18.7374 |
| 1990's | 221 (28.89) | 18.2507 |
| 2000's | 377 (49.28) | 29.6817 |
| 2010's | 146 (19.08) | 24.3611 |
| 2020's | 18 (2.35) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Nakagomi, R; Nakai, D; Sugiyama, Y; Tokui, T; Yawo, H | 1 |
| Hsiang, B; Kirchgessner, TG; Sasseville, V; Wang, Z; Wu, Y; Yang, WP; Zhu, Y | 1 |
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Okumura, H; Sawada, M; Washizuka, Ki | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Ahmad, S; Barrish, JC; Bird, E; Bisaha, S; Blanar, MA; Chang, M; Chen, BC; Chen, X; Cuff, CA; Darienzo, CJ; Giancarli, M; Harrity, T; Huang, C; Janovitz, E; Kennedy, LJ; Li, T; Madsen, CS; Monshizadegan, H; Ngu, K; Nguyen-Tran, V; Reeves, RA; Robl, JA; Ryan, CS; Search, D; Setters, R; Sitkoff, D; Stein, PD; Yin, X; Zahler, R; Zhang, R; Zhao, R; Zhuang, S | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Fukami, M; Fukuda, K; Koga, T; Koike, H; Shimada, Y; Tsujita, Y | 1 |
| Cohen, L; Crommelin, D; Geelhoed-Mieras, T; Griffioen, M; Joles, J; Koomans, H; Krajnc-Franken, M; Van Bloois, L; Van Tol, A; Willekes-Koolschijn, N | 1 |
| Alessandri, C; Peverini, F | 2 |
| Corsini, A; Gabbiani, G; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Behrens-Baumann, W; Thiery, J | 1 |
| Amin, RD; Brunner-Ferber, F; Pentikainen, PJ; Rogers, JD; Saraheimo, M; Schwartz, JI; Schwartz, MS | 1 |
| Eda, T; Hidaka, Y; Kamei, T; Yonemoto, M | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ | 1 |
| Illingworth, DR | 1 |
| Hockwin, O; Schmidt, J; Schmitt, C | 1 |
| Mahoney, EM; Ranadive, SA; Serajuddin, AT | 1 |
| Collins, P; Johnson, A; Owens, D; Robinson, K; Tighe, O; Tomkin, GH | 1 |
| Ditschuneit, H; Ditschuneit, HH; Kuhn, K | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; Kari, PH; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ; Vyas, KP | 1 |
| Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, M | 1 |
| Kalinowski, SS; Mosley, ST; Tanaka, RD | 1 |
| Bain, SC; Jones, AF; Lemon, M; Walker, MR | 1 |
| Ishida, F; Kakubari, K; Kamei, T; Kitani, K; Sato, A; Taguchi, K; Watanabe, K | 1 |
| Aronson, JK; Ng, LL | 1 |
| Maher, VM; Thompson, GR | 1 |
| Bocanegra, TS; Tobert, JA | 1 |
| Hasegawa, K; Koga, T; Kuroda, M; Shimada, Y; Tsujita, Y; Yamazaki, M | 1 |
| Hayaishi, O; Islam, F; Watanabe, Y | 1 |
| Alberts, AW; Bailey, PJ; Bostedor, RG; Germershausen, JI; Hunt, VM; Karkas, JD | 1 |
| Kalinowski, SS; Mosley, ST; Schafer, BL; Tanaka, RD | 1 |
| Tobert, JA | 1 |
| Oliver, MF | 2 |
| Kikuchi, T; Koga, T; Koike, H; Miyazaki, A | 1 |
| Abiko, Y; Ichihara, K; Satoh, K | 1 |
| Smart, AJ; Walters, L | 1 |
| Tonkin, AM | 1 |
| Simes, RJ | 1 |
| Branchi, A; Fiorenza, AM; Rovellini, A; Sommariva, D | 1 |
| Garnett, WR | 2 |
| Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Block, G; Cutler, N; Lines, C; Sramek, J; Stauffer, L; Veroff, A | 1 |
| Amigues, O; Bour Guichenez, G; Cambazard, F; Guy, C; Perrot, JL; Servoz, J | 1 |
| Levenstein, S | 1 |
| Agner, E; Agner, T; Malinowski, J; Meibom, J; Ramsing, D | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Jorge, PA; Metze, K; Ozaki, MR | 1 |
| MacDonald, JS | 1 |
| Shepherd, J | 1 |
| Bär, PR; Contermans, J; Erkelens, DW; Smit, JW | 1 |
| Ichihara, K; Satoh, K | 1 |
| Ichihara, K; Nakai, T; Satoh, K | 1 |
| Carmena, R | 1 |
| Durham, SK; Flint, OP; Gregg, RE; Masters, BA; Palmoski, MJ; Wang-Iverson, D | 1 |
| Faccini, G; Moghetti, P; Muggeo, M; Negri, C; Tosi, F; Travia, D | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Fukaura, Y; Ishikawa, C; Narisawa, T; Tanida, N; Terada, K; Umezawa, A; Yazawa, K | 1 |
| Panuccio, D; Romani, A; Trabatti, MR | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Perani, G; Regazzi, MB; Viganò, M | 1 |
| Cummings, MH; Watts, GF | 1 |
| Steinhagen-Thiessen, E | 1 |
| Arimura, K; Gotow, T; Kuriyama, M; Nakahara, K; Osame, M; Sonoda, Y | 1 |
| Kuriyama, M; Nakahara, K; Osame, M; Yada, T | 1 |
| Sirtori, CR | 1 |
| Ma, L; Morita, I; Murota, S | 1 |
| Lambrecht, LJ; Malini, PL | 1 |
| Emmerich, J | 1 |
| Ashton, CH; Harrison, RW | 1 |
| Corsini, A; Fumagalli, R; Gabbiani, G; Mazzotti, M; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Bremer, J; Lintott, CJ; Scott, RS; Sutherland, WH | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Saheki, A; Tamai, I; Terasaki, T; Tsuji, A | 1 |
| Fukami, M; Fukushige, J; Kogure, Y; Maeda, N; Ogawa, T; Shimada, Y; Tsujita, Y | 1 |
| De Haan, AF; Kastelein, JJ; Kortmann, B; Kroon, AA; Lansberg, PJ; Stalenhoef, AF; Stuyt, PM | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| Holdcroft, C | 1 |
| Golay, A; James, R; Lehmann, T; Pometta, D | 1 |
| Kerry, NL; Nestel, PJ; Roach, PD; Whiting, MJ | 1 |
| Bayne, WF; Gilbert, JD; Hsieh, JY; Matuszewski, BK; Morris, MJ; Ramjit, HG | 1 |
| Bloemendal, H; Cohen, LH; de Vries, AC; Vermeer, MA | 1 |
| Caputo, S; Ghirlanda, G; Greco, AV; Lippa, S; Littarru, GP; Manto, A; Oradei, A; Uccioli, L | 1 |
| Donetti, E; Ferrari, C; Fumagalli, R; Mazzini, G; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Block, GA; Eckernäs, SA; Eriksson, LO; Haigh, JR; Kvidal, P; Neafus, RP; Roos, BE | 1 |
| Stricker, BH; Wolterbeek, R | 1 |
| Bär, PR; Bredman, JJ; Cohen, LH; De Vries, AC; Vermeer, MA | 1 |
| Burg, G; Elsner, P; Krasovec, M | 1 |
| Cohen, LH; Griffioen, M; Jansen, LM; Roodenburg, L; van Vliet, A | 1 |
| Hoshi, K; Ichihara, K; Nakai, T; Satoh, K; Yamato, A | 1 |
| Camerino, DC; De Luca, A; Ferrannini, E; Laico, M; Natuzzi, F; Pierno, S; Roselli, A; Tricarico, D | 1 |
| Martínez-Castelao, A | 1 |
| Boyd, I; England, JD; Halmagyi, GM; Rohan, A; Stewart, P; Walsh, JC | 1 |
| Gotto, AM; Hay, JW | 1 |
| Arnaboldi, L; Corsini, A; Fumagalli, R; Paoletti, R; Quarato, P; Raiteri, M | 1 |
| Del Puppo, M; Galli Kienle, M; Rauli, S | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Benders, AA; Oosterhof, A; Smit, JW; Veerkamp, JH | 1 |
| Holme, I | 1 |
| Cohen, LH; Naaktgeboren, N; van Thiel, GC; van Vliet, AK | 1 |
| Olsson, AG | 2 |
| Thompson, GR | 1 |
| Pedersen, TR; Tobert, JA | 1 |
| Kimura, T; Komai, T; Masuda, H; Nomoto, K; Shinkai, K | 1 |
| Berardesca, E; Brazzelli, V; Distante, F; Perani, G | 1 |
| Dayer, P; Leemann, T; Transon, C | 1 |
| Simons, LA | 1 |
| Hosomi, N; Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Clem, JR | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Hughes, AD | 1 |
| Buckley, BM; Murphy, MB; Vaughan, CJ | 1 |
| Rackley, CE | 1 |
| Kada, M; Komai, T; Kurakata, S; Nomoto, K; Shimada, Y | 1 |
| Dotti, MT; Federico, A; Lindenthal, B; Lütjohann, D; Simatupang, A; von Bergmann, K | 1 |
| Donetti, E; Fumagalli, R; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Masters, P; Shetty, A | 1 |
| Wanner, C | 1 |
| Bolhuis, PA; Cohen, LH; Nègre-Aminou, P; van Thiel, GC; van Vliet, AK | 1 |
| Ganotatis, ES; Jagroop, IA; Mikhailidis, DP; Winder, AF | 1 |
| Rosenson, RS; Tangney, CC | 2 |
| Komatsu, N; Kunitama, M; Miura, Y | 1 |
| Murota, S; Sato-Suzuki, I | 1 |
| Jackson, PR; Payne, JN; Pickin, DM; Ramsay, LE; Ul Haq, I; Yeo, WW | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Angelin, B; Juliusson, G; Vitols, S | 1 |
| Catovsky, D; Clutterbuck, RD; Millar, JL; Newman, A; Powles, RL | 1 |
| Desager, JP; Horsmans, Y | 1 |
| Dal Piaz, A; De Venuto, G; Focher, C; Miori, R; Ramponi, C; Spagnolli, W; Torboli, P | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Applegate, WB; Cushman, W; Elam, MB; Heimberg, M | 1 |
| Cohen, LH; Nègre-Aminou, P; van Erck, M; van Leeuwen, RE; van Thiel, GC; van Vliet, AK | 1 |
| Fager, G; Lennernäs, H | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Roberts, WC | 1 |
| Bhatnagar, D | 1 |
| Durrington, P | 1 |
| Biwa, T; Hakamata, H; Horiuchi, S; Kobori, S; Matsumura, T; Sakai, M; Sato, Y; Shichiri, M; Takemura, T | 1 |
| Itoh, H; Kuriyama, K; Nakagawa, M; Nakata, T; Sasaki, S; Sawada, S; Takeda, K | 1 |
| Scheen, AJ | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Aoki, T; Kimata, H; Kitahara, M; Kojima, J; Nakagawa, S; Nishimura, H; Saito, Y; Sakashita, M; Sato, F; Suzuki, H; Tamaki, T; Toyoda, K; Wada, Y; Yokoo, N | 1 |
| Sussekov, AV | 1 |
| Adkins, JC; Faulds, D | 1 |
| Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C | 1 |
| Smith, SC | 2 |
| Stiffman, MN | 1 |
| Assmann, G; Cullen, P | 1 |
| de Almeida, E; Jorge, PA; Osaki, MR | 1 |
| Aragane, K; Kitamine, T; Kusunoki, J; Ohnishi, H; Yamaura, T | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Grundy, SM | 1 |
| Ellen, RL; McPherson, R | 1 |
| Lane, M; Laskarzewski, P; Stein, EA | 1 |
| Kesäniemi, YA | 1 |
| Kantola, T; Kivistö, KT; Neuvonen, PJ | 1 |
| Danner, M; Hinzpeter, B; Lauterbach, KW; Tacke, J; Troche, CJ | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Pearson, TA | 1 |
| Katznelson, S; Mongini, PK; Perez, RV; Rudich, SM | 1 |
| Smit, AJ | 1 |
| Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH | 1 |
| Mabuchi, H | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Kanaki, T; Kitahara, M; Miyakoshi, C; Saito, Y; Tamaki, T; Tanaka, S; Toyoda, K | 1 |
| Pincus, J | 1 |
| Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L | 1 |
| Eriksson, M | 1 |
| Fujiyama, J; Higuchi, I; Kuriyama, M; Nakagawa, H; Nakahara, K; Osame, M; Sonoda, Y; Yoshidome, H | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Sinzinger, H | 2 |
| Otto, C; Schwandt, P | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Furberg, CD | 1 |
| Chua, TP; Fox, KM; Saia, F | 1 |
| Camerino, C; Conte Camerino, D; De Luca, A; Liantonio, A; Pierno, S | 1 |
| Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Stolley, SN | 2 |
| Kumano, T; Kuriyama, M; Mutoh, T; Nakagawa, H | 1 |
| Bottorff, MB; Cave, DG; Yenkowsky, JP | 1 |
| Elliott, J; Ellis, C; McHaffie, D; Wilkins, G | 1 |
| Kakei, M; Nakata, M; Shiraishi, T; Yada, T | 1 |
| Bush, AC; Carr-Lopez, S; Exstrum, T; Morse, T; Shepherd, M | 1 |
| de Maat, MP; Gevers Leuven, JA; Kluft, C; Mohrschladt, MF; Potter van Loon, BJ | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Hayakawa, T; Inada, M; Miyake, Y; Nishikawa, M; Omoto, S; Shimizu, H; Shouzu, A; Yonemoto, T | 1 |
| Thomas, M | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Basile, V; Capone, D; Gentile, A; Imperatore, P; Pellegrino, T; Stanziale, P | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Frohlich, BH; Gregg, RE; Tesfamariam, B | 1 |
| Bartek, J; Růzicka, V; Stejskal, D | 1 |
| Pedersen, TR | 1 |
| Haneda, T; Kashiwagi, Y; Kawabe, J; Kikuchi, K; Nakamura, Y; Oi, S; Osaki, J | 1 |
| Clare, G; Mann, S | 1 |
| Bloks, V; Hooiveld, GJ; Jansen, PL; Koning, H; Kuipers, F; Loot, AE; Meijer, DK; Müller, M; Scheffer, GL; Van Goor, H; Vos, TA | 1 |
| Asenjo-Barrón, JC; Cárdenas-Vázquez, R; Díaz-Zagoya, JC; Juárez-Oropeza, MA; Martínez, F | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Fukuda, N; Goto, H; Jayasooriya, AP; Ogawa, Y; Sakono, M; Todaka, N; Yamamoto, K | 1 |
| Axel, DI; Fenchel, M; Herzog, UU; Karsch, KR; Riessen, R; Rossmann, H | 1 |
| Seed, M; Weir, MR | 1 |
| Velasco, JA | 1 |
| Farnier, M | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Dobs, AS; Miller, S; Musliner, TA; Neri, G; Shapiro, DR; Tate, AC; Weiss, S | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Stalenhoef, AF; Stehouwer, CD | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Rosenson, RS | 3 |
| Ambrosioni, E; Bacchelli, S; Borghi, C; Costa, FV; Degli Esposti, D; Prandin, MG | 1 |
| Ersoy, FF; Süleymanlar, G; Tuncer, M; Yakupoğlu, G | 1 |
| Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M | 1 |
| Goldman, L; Goldman, PA; Hunink, MG; Prosser, LA; Stinnett, AA; Weinstein, MC; Williams, LW | 1 |
| Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| McNee, W | 1 |
| Breithardt, G; Fan, L; March, KL; Müller, JG; Schmidt, A; Sindermann, JR; Troyer, D; Weigel, KA | 1 |
| Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T | 1 |
| Aboyoun, C; Kaan, A; Keogh, A; Macdonald, P; Mundy, J; Spratt, P | 1 |
| Cobos, A; García-Altés, A; García-Closas, R; Jovell, AJ; Serra-Majem, L | 1 |
| Arnheim, K | 1 |
| Albani, D; Bruno, A; Diomede, L; Fruscella, P; Guglielmotti, A; Mantovani, A; Massimiliano, L; Pinza, M; Polentarutti, N; Romano, M; Salmona, M; Sironi, M; Sottocorno, M; Vecchi, A | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Huang, J; Kiener, PA; Knapp, AC; Starling, G | 1 |
| Brown, WV | 1 |
| Matsuda, T; Muraki, Y; Nagasawa, K; Ohnishi, N; Yokoyama, T | 1 |
| Badimon, JJ; Chesebro, JH; Fallon, JT; Fuster, V; Harris, K; Harris, P; Jayaraman, S; Osende, JI; Rauch, U; Sandler, DA; Vorchheimer, DA | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| García-Altés, A; Jovell, AJ | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Muntinga, JH; Reitsma, WD; Smit, AJ; Ubels, FL; van Doormaal, JJ | 1 |
| Gabbert, HE; Gerards, H; Heuer, T; Pauw, M; Reis, HE | 1 |
| Cheng, JW; Sotiriou, CG | 1 |
| Plutzky, J; Ridker, PM | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Anderson, GM; Jackevicius, CA; Leiter, L; Tu, JV | 1 |
| Kersting, F; Selenka, A; Walch, S | 1 |
| Iwasaki, K; Masuda, N; Morikawa, H; Nakashima, A; Ohtawa, M | 1 |
| Crouch, MA | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Aoki, T; Hasegawa, G; Hori, M; Imaeda, A; Kondo, M; Kondo, Y; Nakamura, N; Nishino, H; Obayashi, H; Ogata, M; Tokuda, K; Yoshikawa, T | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Chiariello, M | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Caroli-Bosc, C; Caroli-Bosc, FX; Delabre, B; Delmont, JP; Demarquay, JF; Le Gall, P; Montet, JC; Pugliese, P; Rampal, P | 1 |
| Wierzbicki, AS | 1 |
| Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T | 1 |
| Ausiello, JC; Chaisson, CE; Stafford, RS; Wang, TJ | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Maeda, K; Minami, M; Yasunari, K; Yoshikawa, J | 1 |
| Orsi, A; Sherman, O; Woldeselassie, Z | 1 |
| Maclaine, GD; Patel, H | 1 |
| Bastarda, A; Grahek, R; Kracun, M; Milivojevic, D | 1 |
| De Gevigney, G; Delahaye, F | 1 |
| Bouzamondo, A; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Galli, C; Pazzucconi, F; Risé, P; Sirtori, CR | 1 |
| Houghton, JL | 1 |
| Golomb, BA; Jaworski, B | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Eberlein, M; Goppelt-Struebe, M; Heusinger-Ribeiro, J | 1 |
| Aldridge, MA; Delucca, GM; Ito, MK | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Iwasaki, K; Kuroda, N; Nakashima, A; Nakashima, K; Ohtawa, M; Wada, M | 1 |
| Le, NA | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Dresselhaus, TR; Henry, RR; Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Shabetai, R | 1 |
| Auer, J; Eber, B | 1 |
| Bottorff, M; Worz, CR | 1 |
| Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW | 1 |
| Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Cesar, LA; Coelho, OR; Mansur, AP; Maranhão, M; Ramires, JA; Sposito, AC | 1 |
| Aeschlimann, SE; Bodemer, A; Carlsson, CM; Carnes, M; McBride, PE; Papcke-Benson, K; Stein, JH | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Arakawa, M; Fujimura, A; Harada, K; Kawaguchi, A; Masada, M; Miyamori, I; Nishiki, K; Ohmori, M; Sakamoto, K; Sugimoto, K; Tsuruoka, S | 1 |
| Adachi, M; Hirano, T; Katagiri, T; Koba, S; Sakai, K; Sakaue, T; Yoshino, G | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Steiner, G | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Fahmy, M; Mahla, G; Mizan, J; Paoletti, R; Southworth, H | 1 |
| Giri, S; Moyna, NM; Thompson, PD; Waters, DD; Weber, KM; White, CM | 1 |
| Iwaki, K; Kakumoto, M; Nakamura, T; Ohmoto, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y | 1 |
| Bertsch, T; Fassbender, K; Kühl, S; Lindenthal, B; Lütjohann, D; Stroick, M; von Bergmann, K | 1 |
| Gaw, A | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| Piliero, PJ | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Aldaghlas, TA; Berthold, HK; Holleran, AL; Kelleher, JK; Lindenthal, B; Sudhop, T; Von Bergmann, K | 1 |
| Andersen, M; Gaist, D; García Rodríguez, LA; Hallas, J; Jeppesen, U; Sindrup, SH | 1 |
| Altieri, PI; Crespo, MJ; Escobales, N; Furilla, RA | 1 |
| Itakura, H | 1 |
| Mach, F | 2 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| DeGruiter, H; Lavie, CJ; Mehra, MR; Milani, RV; Uber, PA; Vivekananthan, K | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Dirschinger, J; Holle, H; Hösl, K; Kastrati, A; Kastrati, D; Mehilli, J; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M | 1 |
| Libby, P; Sukhova, GK; Williams, JK | 1 |
| Liao, JK | 1 |
| Ahn, C; Aronow, WS | 1 |
| Hasegawa, H; Higaki, K; Inazawa, K; Koike, M; Matsumura, T; Nakano, M; Nezasa, K | 1 |
| Aoki, T; Imaeda, A; Kaneko, T; Kondo, Y; Nagase, H; Nakamura, N; Yoshikawa, T | 1 |
| Meadows, SE; Stevermer, JJ | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Császár, A; Márk, L | 1 |
| Lavie, CJ; Mehra, MR; Milani, RV; Park, MH; Scott, RL; Solis, S; Uber, PA; Vivekananthan, K | 1 |
| Bays, HE; Brown, WV; Chitra, R; Hassman, DR; Hutchinson, H; McKenney, J; Miller, E | 1 |
| Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL | 1 |
| Feyen, JH; French, MH; Frith, JC; Güngör, T; Harrity, TW; Rogers, MJ; Staal, A; Swartz, J; Tamasi, J | 1 |
| Holme, I; Tonstad, S | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M | 1 |
| Ferrières, J | 1 |
| Krane, V; Wanner, C | 1 |
| Boh, M; Keber, I; Sebestjen, M | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Leoh, TH; Lo, YL; Loh, LM; Tan, CE | 1 |
| Barouki, R; Gouédard, C; Koum-Besson, N; Morel, Y | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Begg, E; Gardiner, S; Nicholls, G; Scott, R; Sidwell, A | 1 |
| Clark, LT | 1 |
| Faust, M | 1 |
| Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter, M | 1 |
| Conraads, V | 1 |
| Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Arvik, BM; Doraiswamy, PM; Mitton, MW; Wagstaff, LR | 1 |
| Aronow, WS | 1 |
| Diener, HC | 1 |
| Rosenson, RS; Tangney, CC; Wolff, D | 1 |
| Bergdahl, A; Hellstrand, P; Persson, E; Swärd, K | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Cobellis, L; De Leo, V; la Marca, A; Lanzetta, D; Morgante, G; Petraglia, F | 1 |
| Ito, MK | 1 |
| Origasa, H; Yokoyama, M | 1 |
| Mishra, TK; Routray, S | 1 |
| Fujimura, A; Sugimoto, K | 1 |
| Galper, JB; Kim, YJ; Park, HJ; Saul, JP; Shin, DG; Welzig, CM | 1 |
| Romaniv, S; Vecka, M; Zák, A; Zeman, M | 1 |
| de Moerloose, P; Dimitrova, Y; Dunoyer-Geindre, S; Kruithof, EK; Mach, F; Reber, G | 1 |
| Darvesh, S; Martin, E; Rockwood, K; Walsh, R | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Makita, S; Oshima, K; Wajima, T | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Criqui, MH; Dimsdale, JE; Golomb, BA; White, H | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Arai, H; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Tsuchiya, Y; Zhang, B | 1 |
| März, W | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| Berneis, K; Blanche, PJ; Krauss, RM; La Belle, M; Rizzo, M; Shames, DM | 1 |
| Fang, CH; Li, JJ | 1 |
| Tellier, P | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Inoue, Y; Moritan, T; Nagai, R; Ohtomo, K; Yokoyama, I | 1 |
| Doggen, CJ; Heckbert, SR; Lemaitre, RN; Psaty, BM; Smith, NL | 1 |
| Ahmed, M; Griffiths, P | 1 |
| Fujisaki, K; Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Andersson, U; Bergmann Kv, Kv; Bertsch, T; Björkhem, I; Fassbender, K; Kühl, S; Lindenthal, B; Lütjohann, D; Stroick, M; Thelen, K | 1 |
| Bilchick, KC; Blumenthal, RS; Henrikson, CA; Kasper, EK; Skojec, D | 1 |
| Levenson, D | 1 |
| D'Haese, PC; De Broe, ME; Verhulst, A | 1 |
| Eckert, GP; Fechner, T; Franke, C; Igbavboa, U; Johnson-Anuna, LN; Karas, M; Keller, JH; Müller, WE; Schubert-Zsilavecz, M; Wood, WG | 1 |
| Hayashi, M; Ichihara, A; Kaneshiro, Y; Koura, Y; Saruta, T; Tada, Y | 1 |
| Gordon, BR; Levine, DM; Parker, TS; Rosenson, RS; Tangney, CC | 1 |
| Jacobson, TA | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Bezerra, DG; Mandarim-de-Lacerda, CA | 1 |
| Cheng, G; Elmariah, S; Kaplan, FS; Mohler, ER; Wu, B | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Cena, J; Das, D; Mraiche, F; Vollrath, B | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Alsheikh-Ali, AA; Karas, RH | 2 |
| Kawamori, R; Miwa, S; Nishiyama, K; Omura, C; Onuma, T; Takayanagi, N; Tanaka, Y; Watada, H | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Beanlands, R; deKemp, RA; Duchesne, L; Higginson, L; Ling, MC; McPherson, R; Ruddy, TD; Ukkonen, H; Williams, KA | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Bastemir, M; Emral, R; Gullu, S; Lazarus, JH; Parkes, AB | 1 |
| Goto, R; Higashi, K; Ishii, N; Itai, K; Kobori, S; Takahashi, T | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Agrawal, A; Voleti, B | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Gordon, BR; Langman, CB; Levine, DM; Parker, TS; Rosenson, RS; Tangney, CC | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Gotto, AM | 1 |
| Cannon, CP; Ray, KK | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Field, KM | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Davidson, M | 1 |
| Phillips, PS | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 4 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Andersson, U; Björkhem, I; Gutteck, U; Heverin, M; Lütjohann, D; Olin, M; Rentsch, KM; Thelen, KM; von Eckardstein, A | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Kobayashi, S; Koitabashi, Y; Kumai, T; Matsumoto, N; Sekine, S; Watanabe, M; Yanagida, Y | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Aoyama, T; Hara, S; Iwata, H; Kami, M; Kanda, Y; Matsuo, K; Mori, S; Murashige, N; Mutou, Y; Odawara, M; Suzuki, R; Tachibana, S; Takeuchi, K; Yamane, M | 1 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Brophy, JM; Costa, V | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J | 1 |
| Brown, BG | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Kawasaki, A; Kesler, A; Purvin, V; Smith, KH | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Plans-Rubió, P | 1 |
| Buerke, M; Hennen, R; Keller, A; Müller-Werdan, U; Russ, M; Schmidt, H; Werdan, K | 1 |
| Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Cavalca, V; De Franceschi, M; Massironi, P; Tremoli, E; Veglia, F; Werba, JP; Zingaro, L | 1 |
| Ichihara, K | 1 |
| Rini, GB; Rizzo, M | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Carod-Artal, FJ | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abbas, T; Dutta, A; Sivaprasad, U | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Moriguchi, H; Sato, C; Uemura, T | 1 |
| Bloom, ET; Horvath-Arcidiacono, JA; Porter, CM; Tanaka, T | 1 |
| Albers, JJ; Galasko, D; Hazzard, WR; Lee, M; Lee, VM; Leverenz, JB; Li, G; Montine, TJ; Peskind, ER; Petrie, EC; Riekse, RG; Schellenberg, GD; Seubert, P; Vavrek, D; Vuletic, S | 1 |
| Ghribi, O | 1 |
| Inoue, N; Ishikawa, M; Kato, T; Motomura, K; Oikawa, S; Okajima, F; Shimano, H; Takahashi, A; Yamada, N | 1 |
| Becquemont, L; Funck-Brentano, C; Jaillon, P; Letierce, A; Neuvonen, M; Neuvonen, PJ; Verstuyft, C | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Coleman, CI; Dale, KM; Kluger, J; Patel, AA; Shah, SA; White, CM | 1 |
| Brun, ME; Funk, C; Noé, J; Portmann, R | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Angri, V; Calabrò, P; Chiariello, M; Cirillo, P; De Rosa, S; Fiorentino, I; Gargiulo, A; Musto D'Amore, S; Pacileo, M; Petrillo, G; Prevete, N; Sasso, L; Ucci, G | 1 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Doncheva, NI; Nikolov, KV; Vassileva, DP | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| Sylvester, PW; Wali, VB | 1 |
| Araki, S; Asayama, K; Dobashi, K; Shirahata, A | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Crockett, JC; Hughes, A; Idris, AI; Rogers, MJ | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S | 1 |
| Eng, C; Planchon, SM; Teresi, RE; Waite, KA | 1 |
| Dal Pan, G; McAdams, M; Staffa, J | 1 |
| Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Chen, JW; Chen, YH; Huang, SL; Leu, HB; Lin, CP; Lin, WT; Liu, TZ | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| MacDonald, TM; Murphy, MJ; Watson, AD; Wei, L | 1 |
| Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB | 1 |
| Doney, AS; Donnan, PT; Donnelly, LA; Lang, CC; Morris, AD; Palmer, CN; Whitley, AL | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Watson, KE | 2 |
| Beales, IL; Ogunwobi, OO | 1 |
| Hawk, ET; Viner, JL | 1 |
| Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Adachi, H; Imaizumi, T; Iwata, A; Matsunaga, A; Miura, S; Nishikawa, H; Noda, K; Saku, K; Shirai, K; Yanagi, D; Yoshinaga, K; Zhang, B | 1 |
| Criqui, MH; Dimsdale, JE; Golomb, BA; Ritchie, JB; White, HL | 1 |
| Lloyd, D; Petty, D | 1 |
| Barber, MJ; Chasman, DI; Cooper, GM; Durda, JP; Guan, Y; Jenny, NS; Krauss, RM; Lange, LA; Nickerson, DA; Novembre, J; Reiner, AP; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Tracy, RP; Walston, JD | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Doggrell, SA | 1 |
| Xiao, H; Yang, CS | 1 |
| Backman, JT; Neuvonen, PJ; Niemi, M | 1 |
| Ravnskov, U | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Hodgkinson, CP; Ye, S | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Gamie, Z; Graham, S; Linder, T; Tang, QO; Tran, GT; Tsialogiannis, E; Tsiridis, E | 1 |
| Burke, JP; Dhonnchu, TN; Maher, BM; Soo, A; Watson, RW; Wood, AE | 1 |
| Asada, A; Iwaki, H; Iwakiri, K; Kaneshiro, Y; Kobayashi, A; Masada, T; Oda, Y; Takaoka, K | 1 |
| Arima, S; Kai, T; Kanamasa, K; Nakabou, M; Taniyama, Y | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Han, SH; Kim, SJ; Koh, KK; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Ichihara, K; Itagaki, M; Kaneta, S; Kano, S; Satoh, K; Takaguri, A | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Hanson, M; Hoffman, R; Strony, J; Veltri, E | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Satoh, A; Satoh, M | 1 |
| Avigan, M; Barrett, JS; Brinker, AD; Chang, J; Mosholder, A; Nourjah, P; Rowan, C | 1 |
| Kapoor, AS; Majumdar, SR; McAlister, FA; Mohamed, R; Norris, CM; Pretorius, V; Ross, DB | 1 |
| Bhagavan, NV; Ha, CE; Ha, JS; Theriault, AG | 1 |
| Bullock, R; Craig, D; McGuinness, B; Passmore, P | 2 |
| Ozeç, I | 1 |
| Brañes, J; Carvajal, J; Chen-Lin, K; Cuello, M; Gejman, R; Kato, S; Oliva, B; Owen, GI; Sadarangani, A; Smalley, S | 1 |
| Albers, JJ; Dong, W; Vuletic, S | 1 |
| Girardi, G | 1 |
| Fitzgerald, K; Kashanin, D; O'Dowd, F; Robinson, AJ; Walsh, GM; Williams, V | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Barrios-González, J; Miranda, RU | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Keskitalo, JE; Neuvonen, PJ; Niemi, M; Pasanen, MK | 1 |
| Brahmachari, S; Gendelman, HE; Ghosh, A; Matras, J; Pahan, K; Roy, A | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Baker, WL; Coleman, CI; Talati, R; White, CM | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Hickman, J | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Charles, MA; Ishida, B; Kane, JP; Malloy, MJ; Pan, J; Shilian, P; Wu, X | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Confalone, D; Estes, NA; Galper, JB; Karas, RH; Naggar, J; Park, HJ; Rhofiry, J; Shea, J; Welzig, CM | 1 |
| Abt, M; Bech, N; Derks, M; Meneses-Lorente, G; Parr, G; Phelan, M; Turnbull, L; White, AM | 1 |
| Arruda, AP; Breder, I; Coope, A; de Oliveira, HC; Dorighello, Gde G; Milanski, M; Razolli, D; Velloso, LA | 1 |
| Monceau, V; Opolon, P; Pasinetti, N; Pouzoulet, F; Schupp, C; Vozenin, MC | 1 |
| Chang, LC; Chen, JS; Hwang, JC; Lin, YF; Shui, HA | 1 |
| Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ | 1 |
| Fattinger, K; Gubler, C; Hajda, J; Rentsch, KM; Steinert, H; Stieger, B | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Wilke, RA | 1 |
| Fefer, P; Hod, H; Matetzky, S; Novikov, I; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Betteridge, J | 1 |
| Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Belo, VA; Gerlach, RF; Guimaraes, DA; Izidoro-Toledo, TC; Tanus-Santos, JE | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Shi, J; Xue, Z | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Kageji, T; Kanematsu, Y; Kinouchi, T; Kitazato, KT; Matsushita, N; Nagahiro, S; Satomi, J; Shimada, K; Tada, Y; Yagi, K | 1 |
| Biasibetti, R; Bobermin, L; Gonçalves, CA; Quincozes-Santos, A; Rodrigues, L; Tramontina, AC; Tramontina, F; Wartchow, KM | 1 |
| Abe-Dohmae, S; Fitzgerald, ML; Iwamoto, N; Tanaka, N; Yokoyama, S | 1 |
| Ali, OF; Butrous, GS; Growcott, EJ; Wharton, J | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Chakraborty, K; Harirforoosh, S; Hsi, L; Krishnan, K; Menter, DG; Newman, RA; Ramsauer, VP; Yang, P | 1 |
| Hong, SJ; Kim, PS; Ko, JH; Mustoe, TA; Zhao, Y | 1 |
| Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C | 1 |
| Anastasiou-Nana, M; Andreadou, I; Farmakis, D; Iliodromitis, EK; Kremastinos, DT; Papalois, A; Papapetropoulos, A; Prokovas, E; Sigala, F; Spyridaki, K; Zoga, A | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Dimsdale, JE; Evans, MA; Golomb, BA; White, HL | 1 |
| de Oliveira, RB; Oliveira, MA; Silva, TD; Vianna-Soares, CD | 1 |
| Haughey, NJ; Maragakis, NJ; Murinson, BB | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Jin, J; Kim, BY; Kim, DE; Kim, EK; Kim, JS; Lee, DK; Lee, H; Park, EJ; Shin, IJ | 1 |
| Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E | 1 |
| Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Okuyan, M; Yaris, E | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Basraon, SK; Costantine, MM; Hankins, GD; Longo, M; Makhlouf, M; Menon, R; Saade, GR | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Devi, K; Ghodke, RM; Tour, N | 1 |
| Bauzon, F; Krauss, RM; Kuang, YL; Mangravite, LM; Medina, MW; Naidoo, D; Stevens, K; Theusch, E | 1 |
| Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J | 1 |
| Cereza, G; Figueras, A; Tarapués, M | 1 |
| Golomb, BA; Koperski, S | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Ganesan, S; Ito, MK | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Atehortúa, L; Chegwin-Angarita, C; Diaz, GJ; Jeannette Nieto-Ramirez, I; Rojas L, JR; Sepúlveda, L | 1 |
| Girardi, G; Gonzalez, JM; Jansen, MA; Lennen, RJ; Marshall, I; Pedroni, SM; Serio, A; Wade, J | 1 |
| Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ | 1 |
| Aukrust, P; Holven, KB; Nenseter, MS; Ose, L | 1 |
| Chang, CH; Chen, YC; Hsu, YM; Lin, FH; Loo, ST; Sadhasivam, S; Savitha, S | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Alupei, MC; Banciu, M; Cristian, FB; Licarete, E | 1 |
| Asarnow, D; Caffrey, CR; Long, T; Rojo-Arreola, L; Singh, R; Suzuki, BM | 1 |
| Al-Hamaq, AO; Barakat, L; Bener, A; Dogan, M | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Baba, A; Kazama, I; Maruyama, Y | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Furukubo, T; Izumi, S; Minegaki, T; Nishiguchi, K; Oda, T; Ogino, H; Shinmoto, T; Tachiki, H; Tsujimoto, M; Uchiyama, H; Yamakawa, T; Yoshida, T | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Cha, TJ; Cho, KI; Heo, JH; Kim, HS; Kim, KL; Kim, SJ; Lee, JW; Lee, SJ; Shim, IK; Zhang, YH | 1 |
| Albers, M; Baumeister, SE; Kroemer, HK; Meyer zu Schwabedissen, HE; Nauck, M; Rimmbach, C; Siegmund, W; Völzke, H; Wallaschofski, H | 1 |
| Aleksandrowicz, M; Drapala, A; Kozniewska, E; Sikora, M; Skrzypecki, J; Ufnal, M; Zera, T | 1 |
| Arora, RC; Bellan, D; Freed, DH; Kirshenbaum, LA; Li, Y; Müller, AL; Ngo, MA; Sran, K | 1 |
| Einecke, D | 1 |
| Chang, CY; Huang, CT; Hung, LY; Kao, CY; Li, JD; Lim, JH; Ruan, JW; Statt, S; Wu, R | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Srinivas, NR | 2 |
| Cogo-Müller, K; Cuzzullin, MC; de Andrade, ED; Franco, GC; Graziano, TS; Groppo, FC; Schwartz-Filho, HO | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| Hua, L; Li, Y; Liu, H; Wang, D; Xiong, X; Zhao, H | 1 |
| Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M | 1 |
| Anzalone, DA; Cain, VA; Friday, KE; Lewis, SJ; Welty, FK | 1 |
| Kokkola, T; Kuusisto, J; Laakso, M; López Rodríguez, M; Modi, S; Stančáková, A; Yaluri, N | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Barrett, DA; De Moor, CH; Gandhi, RD; Gershkovich, P; Hoo, CW; Lee, JB; Taha, DA | 1 |
| Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Tong, S | 1 |
| Hong, JM; Lee, JS; Lim, SG; Park, RW; Shin, D; Yoon, D | 1 |
| Cooper, LS; Dunning, A; Fiuzat, M; Fleg, JL; Kelly, JP; Keteyian, SJ; Kitzman, DW; Kraus, WE; Leifer, ES; Mentz, RJ; O'Connor, CM; Pina, IL; Schulte, PJ; Whellan, DJ | 1 |
| Corkum, A; Fisher, J; Minard, LV; Saleh, A; Sketris, I; Zhang, Y | 1 |
| Jiang, M; Liu, TT; Pan, DQ; Shi, JH; Wang, Q | 1 |
| Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S | 1 |
| Beckerman, JG; Chang, SC; Gluckman, TJ; Grunkemeier, GL; Sanz, M; Wang, M | 1 |
| Adams-Huet, B; Ahmad, Z; Khine, H; Yuet, WC | 1 |
| Kokkola, T; Modi, S; Yaluri, N | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Aganov, AV; Aganova, OV; Galiullina, LF; Klochkov, VV; Latfullin, IA; Musabirova, GS | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Barrett, DA; Bruce, KD; de Moor, CH; Eckel, RH; Gershkovich, P; Lee, JB; Sungelo, M; Taha, DA; Zgair, A | 1 |
| Asping, M; Dela, F; Dohlmann, TL; Helge, JW; Larsen, S; Stride, N; Søgaard, D | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Corradi, JP; Dicks, R; Duan, Y; Grady, J; Mather, JF; Noyes, A; Waszynski, C | 1 |
| Carroll, JA; Chesebro, B; Phillips, K; Race, B; Striebel, JF | 1 |
| Ho, JE | 1 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Burale, S; Carson, RA; Chandran, UR; DeFranco, DB; Frahm, KA; Franks, AL; Monaghan, AP; Phan, JV; Rudine, AC; Silswal, N; Tally, SJ; Waldman, JK | 1 |
| Cook, RL; Dave, CV; Hartzema, AG; Park, H; Winterstein, AG | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Clifton, J; Lang, T; Neher, J; Safranek, S | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Krychtiuk, KA; Lenz, M; Pentz, R; Stojkovic, S; Thaler, B; Wojta, J; Zuckermann, A | 1 |
| Aschmann, HE; Puhan, MA; Yebyo, HG | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Duleba, AJ; Hawkins, AB; Sokalska, A; Yamaguchi, T | 1 |
| Aganov, A; Galiullina, LF; Huster, D; Klochkov, V; Scheidt, HA | 1 |
| Chen, Y; Li, LB; Tang, DP; Wei, JJ; Zhang, J; Zhuang, ZH | 1 |
| Albertsson, M; Holmqvist, A; Kotti, A; Sun, XF | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Au, A; Basu, S; Collier, VJ; Hopkin, G; Naci, H; Yudkin, JS | 1 |
| Dobs, AS; Duprez, DA; Folsom, AR; Konety, SH; Kronmal, RA; Oluleye, OW; Ouyang, P; Vaidya, DM; Yarmohammadi, H | 1 |
| Almeida, RS; Bosqui, LR; Conchon-Costa, I; Costa, IN; da Silva, SS; Machado, LF; Miranda-Sapla, MM; Navarro, IT; Panagio, LA; Pavanelli, WR; Sanfelice, RADS | 1 |
| Isaka, Y; Nakamura, T; Nakayama, S; Taguchi, N; Tanaka, M | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Fenning, AS; Irwin, JC; Vella, RK | 1 |
| Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C | 1 |
| Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Kaitu'u-Lino, TJ; Mangwiro, YT; Tong, S | 1 |
| Cheng, X; Dolivo, DM; Galiano, RD; Hong, SJ; Jia, S; Mustoe, TA; Salcido, J; Xie, P | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Abraldes, JG; Al-Karaghouli, M; Cabrera Garcia, L; Kalainy, S; Sung, S | 1 |
| Anagnostis, P; Bosdou, JK; Goulis, DG; Hatzimouratidis, K; Ioannidou, PG; Mikhailidis, DP; Papanikolaou, D | 1 |
| Barwiolek, M; Budny, M; Ciarkowska, A; Kozakiewicz, A; Loch, JI; Sokolowska, Z; Wojtczak, A; Wujak, M | 1 |
| Corbella, E; Corbella, X; Díaz-Díaz, JL; Martínez-Porqueras, R; Pintó, X; Rodríguez-Sánchez, MA; Ruíz-García, A; Sánchez-Ruíz-Granado, E; Sarasa, I; Suárez-Tembra, M; Trias, F | 1 |
| Chowdhury, EK; Curtis, AJ; Ernst, ME; McNeil, JJ; Murray, AM; Nelson, MR; Reid, CM; Ryan, J; Tonkin, AM; Wolfe, R; Woods, RL; Zhou, Z; Zoungas, S | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Chen, B; Chen, SP; Cheng, RY; Lin, Y; Tsui, L; Xu, S; Ye, P | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Furugen, A; Kobayashi, M; Mukai, Y; Narumi, K; Sakuma, T; Yamaguchi, A | 1 |
| Filppula, AM; Hirvensalo, P; Keskitalo, J; Kiiski, JI; Lönnberg, KI; Mustaniemi, AL; Niemi, M; Tornio, A | 1 |
| Ho, HA; Jung, BC; Kim, S; Lee, SJ; Lee, W; Min, JO; Park, SJ | 1 |
131 review(s) available for pravastatin and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
Topics: Adult; Animals; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Pravastatin; Rats; Risk Factors; Simvastatin; Time Factors | 1992 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
[Hypercholesterolemia: therapeutic approach].
Topics: Adult; Aged; Anticholesteremic Agents; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1995 |
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Topics: Anticholesteremic Agents; Biological Availability; Comorbidity; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1995 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rhabdomyolysis; Risk Factors; Simvastatin; Species Specificity; Structure-Activity Relationship; Tissue Distribution | 1993 |
[Side effects of cholesterol synthesis inhibitors].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Middle Aged; Pravastatin; Rhabdomyolysis; Simvastatin | 1993 |
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lovastatin; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Topics: Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin | 1996 |
Statins do more than just lower cholesterol.
Topics: Anticholesteremic Agents; Arteries; Arteriosclerosis; Blood; Cholesterol; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Topics: Aged; Cholesterol; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Male; Pravastatin; Pregnancy; Simvastatin | 1996 |
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Topics: Anticholesteremic Agents; Arteriosclerosis; Brain; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver; Lovastatin; Pravastatin; Simvastatin | 1997 |
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin | 1997 |
Review of recent clinical trials of lipid lowering in coronary artery disease.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin; Simvastatin | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Comparison of statins in hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1998 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Simvastatin | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
Vastatin trials: lessons from hypertension history.
Topics: Aged; Anticholesteremic Agents; Controlled Clinical Trials as Topic; Humans; Hypertension; Pravastatin; Simvastatin; Treatment Outcome | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins have other beneficial properties besides their cholesterol lowering effect].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lovastatin; Pravastatin; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Are there differences in various statins?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
[The new debate on cholesterol: is the lowest level the best?].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Guidelines as Topic; Humans; Hypercholesterolemia; Male; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin; Sweden | 1999 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Biological basis for statin therapy in stroke prevention.
Topics: Animals; Humans; Lovastatin; Pravastatin; Simvastatin; Stroke | 2000 |
Non-lipid-related effects of statins.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Esterification; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Simvastatin | 2000 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Topics: Blood Coagulation; Blood Platelets; Blood Pressure; Blood Viscosity; Cholesterol; Coronary Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth; Pravastatin; Simvastatin | 2000 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[Treatment with statins for the reduction of cardiovascular risk].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Factors; Simvastatin | 2001 |
[Secondary prevention of coronary artery disease with lipid-lowering drugs].
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Morbidity; Myocardial Revascularization; Patient Selection; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[Does statin therapy reduce the risk of stroke? A meta-analysis].
Topics: Age Distribution; Cardiovascular Diseases; Cause of Death; Effect Modifier, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Primary Prevention; Risk; Risk Factors; Simvastatin; Stroke; Survival Analysis; Treatment Outcome | 2001 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Topics: Aged; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isoenzymes; Itraconazole; Lovastatin; Male; Middle Aged; Muscular Diseases; Pravastatin; Rhabdomyolysis; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
The use of fibrates and of statins in preventing atherosclerosis in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hypolipidemic Agents; Pravastatin; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Healthy ageing: addressing acute coronary syndrome?
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Australia; Coronary Disease; Endothelium, Vascular; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; New Zealand; Pravastatin; Risk Factors; Sex Factors; Simvastatin; Syndrome; United States | 2001 |
Beyond lipid lowering: the role of statins in vascular protection.
Topics: Animals; Cardiovascular Diseases; Coronary Artery Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Physiologic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; Stroke | 2002 |
Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Simvastatin | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
[Primary and secondary prevention of coronary disease by statins].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1999 |
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin | 2003 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Statin-associated memory loss: analysis of 60 case reports and review of the literature.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Memory Disorders; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Hypercholesterolemia. The evidence supports use of statins.
Topics: Aged; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Pravastatin; Simvastatin | 2003 |
Role of the pharmacist in establishing lipid intervention programs.
Topics: Clinical Trials as Topic; Humans; Hyperlipidemias; Pharmacies; Pharmacists; Pharmacy Service, Hospital; Pravastatin; Program Development; Simvastatin; United States | 2003 |
Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry.
Topics: Aggression; Angiotensin-Converting Enzyme Inhibitors; Cholesterol; Cognition; Humans; Hypercholesterolemia; Pravastatin; Randomized Controlled Trials as Topic; Serotonin; Simvastatin; United States | 2004 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Statins and secondary prevention of coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Survival Analysis; Treatment Outcome | 2004 |
Treatment of hyperlipidemia in cardiac transplant recipients.
Topics: Algorithms; Coronary Artery Disease; Endothelium, Vascular; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Pravastatin; Simvastatin | 2004 |
Statins: can the new generation make an impression?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Statin-associated myasthenia gravis: report of 4 cases and review of the literature.
Topics: Aged; Autoantibodies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myasthenia Gravis; Pravastatin; Pyrimidines; Receptors, Cholinergic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Myocardial dysfunction].
Topics: Animals; Cardiomyopathies; Clinical Trials as Topic; Coenzymes; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Stunning; Myocardium; Oils; Pravastatin; Simvastatin; Solubility; Ubiquinone; Water | 2006 |
Statins, fracture risk, and bone remodeling: What is true?
Topics: Bone Remodeling; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Myocardial Ischemia; Osteoporosis; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Impact of gender on statin efficacy.
Topics: Age Distribution; Aged; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Odds Ratio; Pravastatin; Probability; Prognosis; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Severity of Illness Index; Sex Distribution; Simvastatin; Survival Analysis; Treatment Outcome | 2007 |
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
What is the evidence in favor of low-dose statin therapy in 2008?
Topics: Cardiovascular Diseases; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Topics: Animals; Biological Availability; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Nonprescription Drugs; Pharmacogenetics; Pravastatin; Simvastatin | 2008 |
Statins: under investigation for increasing bone mineral density and augmenting fracture healing.
Topics: Animals; Atorvastatin; Bone Density; Bone Morphogenetic Protein 2; Clinical Trials as Topic; Fracture Healing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Osteoclasts; Pravastatin; Pyrroles; Simvastatin; Vascular Endothelial Growth Factor A | 2008 |
Statins for the prevention of dementia.
Topics: Alzheimer Disease; Anticholesteremic Agents; Cognition; Dementia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2009 |
Biotechnological production and applications of statins.
Topics: Acyltransferases; Anticholesteremic Agents; Aspergillus; Biotechnology; Fermentation; Lovastatin; Pravastatin; Simvastatin | 2010 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Blood Glucose; Blood Pressure; Body Size; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Patient Selection; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Statins for the prevention of dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Cognition; Dementia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Pravastatin; Simvastatin | 2021 |
The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review.
Topics: Adult; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Semen; Simvastatin; Sperm Motility | 2021 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
150 trial(s) available for pravastatin and simvastatin
| Article | Year |
|---|---|
Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1992 |
Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Simvastatin | 1992 |
HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Phenotype; Pravastatin; Simvastatin; Time Factors | 1990 |
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, HDL; Lipoproteins, VLDL; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1987 |
Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Ischemia; New Zealand; Pravastatin; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1995 |
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholesterol; Delayed-Action Preparations; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Receptors, LDL; Simvastatin | 1995 |
Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1995 |
A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.
Topics: Adult; Anticholesteremic Agents; Double-Blind Method; Ergometry; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscles; Permeability; Pravastatin; Prospective Studies; Simvastatin; Statistics as Topic | 1995 |
Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Cyclosporine; Follow-Up Studies; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Time Factors; Triglycerides | 1994 |
Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1994 |
Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1993 |
Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Brain; Cholesterol; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Liver; Lovastatin; Male; Pravastatin; Psychomotor Performance; Simvastatin; Sleep; Test Anxiety Scale | 1994 |
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Topics: Adult; Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Topics: Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
Topics: Adult; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1993 |
The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
Topics: Adult; Aged; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Polysomnography; Pravastatin; Simvastatin; Sleep; Sleep Wake Disorders | 1993 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Sleep; Treatment Outcome | 1993 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
[Statin therapy of individuals with high risk for coronary disease].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Male; Pravastatin; Risk Factors; Scotland; Simvastatin | 1996 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Acyl Coenzyme A; Blood Viscosity; Cholesterol; Enzyme Inhibitors; Female; Fibrinogen; Hematocrit; Hemorheology; Humans; Hyperlipoproteinemias; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1996 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Topics: Adult; Aged; B-Lymphocytes; Cell Division; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukemia, Lymphoid; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Mitogens; Pravastatin; Simvastatin; Thymidine; Tumor Cells, Cultured | 1997 |
[Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Severity of Illness Index; Simvastatin; Time Factors | 1996 |
Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mixed Function Oxygenases; Pravastatin; Simvastatin | 1998 |
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Topics: Adolescent; Adult; Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Efficacy of three statins at lower maintenance doses.
Topics: Adult; Aged; Anticholesteremic Agents; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1999 |
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Chromatography, High Pressure Liquid; Coenzymes; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1999 |
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Pravastatin; Simvastatin | 1999 |
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)].
Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Pravastatin; Proteins; Simvastatin | 1998 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Quality of Life; Sexual Behavior; Simvastatin | 1999 |
Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients.
Topics: Adult; Cholesterol; Cholesterol, LDL; Gonadal Steroid Hormones; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Spermatogenesis; Spermatozoa; Testis; Testosterone; Triglycerides | 2000 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Simvastatin | 2000 |
Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients.
Topics: Acute Disease; Adult; Anticholesteremic Agents; Female; Graft Rejection; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney Transplantation; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin | 2000 |
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides | 2000 |
Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Middle Aged; Postoperative Care; Pravastatin; Safety; Simvastatin; Survival Rate; Treatment Outcome; Tunica Intima | 2000 |
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.
Topics: Anticholesteremic Agents; Blood Coagulation; Cardiovascular Diseases; Cell Adhesion Molecules; Endothelium, Vascular; Humans; Hypercholesterolemia; Middle Aged; Pravastatin; Simvastatin; Solubility; Vasomotor System | 2000 |
Effects of cholestyramine on vitamin E levels in patients treated with statins.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, LDL; Cholestyramine Resin; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Vitamin E | 2000 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Angiography; Coronary Disease; Exercise Test; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Simvastatin | 2001 |
The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia.
Topics: Aged; Aged, 80 and over; Ascorbic Acid; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Long-Term Care; Male; Pravastatin; Simvastatin; Vasodilation; Vitamin A | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Biotransformation; Chromatography, Liquid; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Hypericum; Male; Mass Spectrometry; Phytotherapy; Pravastatin; Simvastatin | 2001 |
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.
Topics: Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2001 |
The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation.
Topics: Aged; Analysis of Variance; Blood Platelets; Chi-Square Distribution; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Probability; Reference Values; Simvastatin; Treatment Outcome | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
[Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Topics: Adult; Cholesterol; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Statin treatment following coronary artery stenting and one-year survival.
Topics: Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Simvastatin; Stents; Survival Rate | 2002 |
Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Topics: Adolescent; Adult; Cholesterol, LDL; Coronary Disease; Female; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Survival Analysis; Treatment Outcome | 2002 |
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Topics: Anticholesteremic Agents; Brachial Artery; Cholesterol; Cholesterol, HDL; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasodilation | 2002 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome | 2003 |
Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Humans; Hypercholesterolemia; Lipid Peroxidation; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 2003 |
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2004 |
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Chemotherapy, Adjuvant; Coronary Artery Disease; Death, Sudden, Cardiac; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Simvastatin | 2003 |
Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Cross-Over Studies; Diuretics; Female; Furosemide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin | 2003 |
Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness.
Topics: Adult; Aged; Biomarkers; Blotting, Western; Cross-Over Studies; Electrocardiography, Ambulatory; Female; GTP-Binding Protein alpha Subunit, Gi2; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lymphocytes; Male; Middle Aged; Parasympathetic Nervous System; Pravastatin; Predictive Value of Tests; Proto-Oncogene Proteins; Simvastatin; Single-Blind Method | 2003 |
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Coronary Vessels; Female; Humans; Hypercholesterolemia; Hyperemia; Hypolipidemic Agents; Male; Myocardium; Pravastatin; Simvastatin; Stress, Physiological; Tomography, Emission-Computed; Vasodilation | 2004 |
Long-term effects of statins on arterial pressure and stiffness of hypertensives.
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Cholesterol; Elasticity; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prospective Studies; Pulsatile Flow; Simvastatin; Single-Blind Method | 2005 |
Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia.
Topics: Arteriosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pravastatin; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Simvastatin; Tumor Necrosis Factor Decoy Receptors | 2004 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microcirculation; Middle Aged; Positron-Emission Tomography; Pravastatin; Simvastatin; Time Factors; Ultrasonography | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.
Topics: Adult; Apoptosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lymphocytes; Male; Middle Aged; Pravastatin; Pyridines; Simvastatin; Thyroid Gland; Thyroiditis, Autoimmune | 2005 |
HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients.
Topics: Aged; Carotid Artery, Common; Cholesterol; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Tunica Intima; Tunica Media | 2005 |
Short-term reduction in bone markers with high-dose simvastatin.
Topics: Adult; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Collagen; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Osteocalcin; Pravastatin; Simvastatin | 2005 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects.
Topics: Adult; Animals; Beverages; Biological Availability; Blotting, Western; Carrier Proteins; Citrus sinensis; Cross-Over Studies; Dietary Carbohydrates; Female; Food-Drug Interactions; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Intestines; Male; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2006 |
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides | 2005 |
A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels.
Topics: Adult; Aged; Cholesterol, LDL; Chromans; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Female; gamma-Tocopherol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pravastatin; Propionates; Prospective Studies; Simvastatin | 2007 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Brain; Cholesterol; Cholesterol, LDL; F2-Isoprostanes; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Neuroprotective Agents; Peptide Fragments; Pravastatin; Simvastatin; tau Proteins; Triglycerides | 2006 |
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Prospective Studies; Simvastatin; Tissue Distribution | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2006 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography | 2008 |
Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2008 |
Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diastole; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Simvastatin; Stroke; Systole; Treatment Outcome | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.
Topics: Adiponectin; Adipose Tissue; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol; Dyslipidemias; Female; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin | 2008 |
Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients.
Topics: Adiponectin; C-Reactive Protein; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Leptin; Lipoproteins; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Vasodilation | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides | 2008 |
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Simvastatin | 2011 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Differential effects of statins (pravastatin or simvastatin) on ventricular ectopic complexes: Galpha(i2), a possible molecular marker for ventricular irritability.
Topics: Adult; Aged; Biomarkers; Blotting, Western; Cross-Over Studies; Densitometry; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Follow-Up Studies; GTP-Binding Protein alpha Subunit, Gi2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prognosis; Retrospective Studies; Simvastatin; Treatment Outcome; Ventricular Premature Complexes | 2010 |
Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Topics: Adult; Amides; Anticholesteremic Agents; Area Under Curve; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Esters; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfhydryl Compounds; Sulfonamides | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial.
Topics: Adult; Cholesterol, LDL; Exercise Test; Fatigue; Female; Humans; Hypolipidemic Agents; Male; Outcome Assessment, Health Care; Pharmacovigilance; Physical Exertion; Pravastatin; Self Report; Sex Factors; Simvastatin | 2012 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides; United States | 2016 |
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
Topics: Aged; Atorvastatin; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Oxygen Consumption; Pravastatin; Quality of Life; Simvastatin; Stroke Volume; Treatment Outcome; Walk Test | 2016 |
The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study.
Topics: Adult; Blood Glucose; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Middle Aged; Mitochondria, Muscle; Muscle Fibers, Skeletal; Oxygen Consumption; Pravastatin; Simvastatin; Ubiquinone | 2017 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.
Topics: Adult; Atorvastatin; Choice Behavior; Decision Support Techniques; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Patient Preference; Pilot Projects; Pravastatin; Precision Medicine; Psychometrics; Rosuvastatin Calcium; Self Efficacy; Simvastatin | 2019 |
Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Disabled Persons; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Primary Prevention; Proportional Hazards Models; Rosuvastatin Calcium; Simvastatin | 2022 |
488 other study(ies) available for pravastatin and simvastatin
| Article | Year |
|---|---|
Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.
Topics: Animals; Anion Transport Proteins; Biological Transport; Carbon Radioisotopes; Carrier Proteins; Cholates; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oocytes; Pravastatin; Rats; Simvastatin; Xenopus laevis | 1999 |
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
Topics: Amino Acid Sequence; Animals; Anion Transport Proteins; Base Sequence; Biological Transport; Carrier Proteins; Dehydroepiandrosterone Sulfate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Pravastatin; Rats; Taurocholic Acid | 1999 |
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738.
Topics: Animals; Benzylamines; Cholesterol; Dogs; Enzyme Inhibitors; Humans; In Vitro Techniques; Microsomes, Liver; Oxygenases; Rats; Squalene Monooxygenase; Structure-Activity Relationship; Triglycerides; Tumor Cells, Cultured | 2004 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
Topics: Administration, Oral; Animals; Biological Availability; Chemical and Drug Induced Liver Injury; Cholesterol; Crystallography, X-Ray; Dogs; Female; Guinea Pigs; Haplorhini; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Models, Molecular; Muscle Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Organ Specificity; Pravastatin; Rats; Rats, Wistar; Simvastatin; Spleen; Sterols; Testis; Tissue Distribution | 1992 |
Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusion Pumps, Implantable; Injections, Subcutaneous; Lovastatin; Pravastatin; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Simvastatin | 1992 |
Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation.
Topics: Animals; Anticholesteremic Agents; Cell Division; Cells, Cultured; Humans; Lovastatin; Myocardium; Pravastatin; Rats; Simvastatin | 1992 |
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Cataract; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Pravastatin; Rabbits; Simvastatin | 1992 |
Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1992 |
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Benzylamines; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Fibrinogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Nifedipine; Platelet-Derived Growth Factor; Pravastatin; Simvastatin; Sterols; Swine; Thiophenes | 1992 |
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship | 1992 |
[The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Topics: Adult; Cataract; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lovastatin; Middle Aged; Pravastatin; Refraction, Ocular; Risk Factors; Simvastatin; Visual Acuity | 1991 |
Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Topics: Anticholesteremic Agents; Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Solubility; Structure-Activity Relationship | 1991 |
Pravastatin and simvastatin for hypercholesterolemia.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Muscular Diseases; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hypercholesterolemia; Leukocytes; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Comparison of different HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1991 |
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Topics: Animals; Biliary Tract; Cholestasis; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Microsomes, Liver; Muscular Diseases; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin | 1991 |
Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
Topics: Animals; Aorta; Cell Division; Cells, Cultured; Depression, Chemical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscle, Smooth, Vascular; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Thymidine | 1991 |
Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
Topics: Acetates; Animals; Cholesterol; Cricetinae; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Liver; Lovastatin; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Time Factors | 1991 |
Apolipoprotein(a) and ischaemic heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins A; Coronary Disease; Heptanoic Acids; Humans; Liver; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits.
Topics: Animals; Bile; Cholesterol; Cholesterol, Dietary; Heptanoic Acids; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Microsomes, Liver; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL; Simvastatin; Statistics as Topic; Sterol O-Acyltransferase | 1990 |
Lipid lowering drugs.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Acetates; Acetic Acid; Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Kinetics; L Cells; Lens, Crystalline; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen | 1990 |
Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Binding, Competitive; Brain; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Naphthalenes; Pravastatin; Rats; Simvastatin | 1990 |
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
Topics: Adrenal Glands; Animals; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Lovastatin; Male; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen; Testis; Tissue Distribution | 1989 |
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lens, Crystalline; Liver; Lovastatin; Male; Naphthalenes; Organ Specificity; Pravastatin; Rabbits; Rats; Rats, Inbred Strains; Simvastatin; Species Specificity | 1989 |
Statins prevent coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1995 |
Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Pravastatin; Simvastatin; Spleen; Sterols; Testis | 1995 |
Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Blood Pressure; Carbohydrate Metabolism; Cholesterol; Dogs; Energy Metabolism; Female; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Stunning; Myocardium; Pravastatin; Simvastatin; Ventricular Function, Left | 1993 |
Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Cost Control; Cost-Benefit Analysis; Health Care Costs; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1994 |
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Cholesterol Esters; Diterpenes; Farnesol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Topics: Aged; Alcoholism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Porphyria Cutanea Tarda; Pravastatin; Simvastatin | 1994 |
Pravastatin versus simvastatin--what happens in the real world?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Product Surveillance, Postmarketing; Simvastatin | 1995 |
Effect of systemic treatment with cholesterol-lowering drugs on the skin barrier function in humans.
Topics: Adult; Aged; Anticholesteremic Agents; Biological Availability; Cholesterol; Erythema; Female; Galvanic Skin Response; Humans; Hypercholesterolemia; Irritants; Lovastatin; Male; Middle Aged; Patch Tests; Permeability; Pravastatin; Simvastatin; Skin; Sodium Dodecyl Sulfate; Water Loss, Insensible | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Aorta, Thoracic; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Male; Pravastatin; Rabbits; Simvastatin; Vasodilation | 1994 |
Perspective on cataractogenic potential of HMG-CoA reductase inhibitors.
Topics: Animals; Cataract; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Rats; Simvastatin | 1995 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts.
Topics: Adenosine Diphosphate; Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Fluvastatin cost considerations.
Topics: Drug Costs; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1994 |
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia.
Topics: Adenosine Diphosphate; Animals; Cell Fractionation; Glutamic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Liver; Lovastatin; Male; Mitochondria, Liver; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Succinates | 1994 |
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Topics: Animals; Anticholesteremic Agents; Blood Proteins; Cells, Cultured; Cholesterol; Drug Stability; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Mevalonic Acid; Muscle, Skeletal; Pravastatin; Pregnancy; Protein Binding; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Chorionic Gonadotropin; Gonadal Steroid Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Testis | 1995 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Anticarcinogenic Agents; Carcinogens; Cholesterol; Colonic Neoplasms; Dimethylhydrazines; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred ICR; Pravastatin; Simvastatin | 1994 |
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
Topics: Aged; Cholesterol; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1994 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Topics: Action Potentials; Animals; Electric Stimulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myotonia; Pravastatin; Rabbits; Simvastatin | 1994 |
Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
Topics: Animals; Calcium; Cell Survival; Cells, Cultured; Cytosol; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Pravastatin; Rats; Simvastatin | 1994 |
Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors.
Topics: Animals; Blood; Carotid Arteries; Cattle; Cell Movement; Cholesterol; Culture Media; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin.
Topics: Anticholesteremic Agents; Cholesterol; Double-Blind Method; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Topics: Acyclic Monoterpenes; Animals; Aorta; Cell Division; Cells, Cultured; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Farnesol; Fatty Acids, Monounsaturated; Femoral Artery; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Squalene; Terpenes | 1993 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
Topics: Acetates; Acetic Acid; Animals; Biological Transport; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Cattle; Cells, Cultured; Endothelium, Vascular; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Perfusion; Pravastatin; Rats; Rats, Wistar; Sensitivity and Specificity; Simvastatin; Temperature | 1993 |
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Topics: Administration, Oral; Animals; Cholesterol; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Male; Muscles; Muscular Diseases; Pravastatin; Rabbits; Simvastatin; Ubiquinone | 1993 |
Simvastatin, pravastatin and lovastatin: three options for lowering cholesterol.
Topics: Anticholesteremic Agents; Drug Costs; Drug Interactions; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit.
Topics: Animals; Bile; Cholesterol; Hypolipidemic Agents; Leukocytes, Mononuclear; Lipids; Liver; Lovastatin; Male; Pravastatin; Rabbits; Receptors, LDL; Simvastatin | 1993 |
Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Topics: Anticholesteremic Agents; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Trimethylsilyl Compounds | 1993 |
Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cell Membrane; Cholesterol; Fatty Acids; Humans; Lens Cortex, Crystalline; Lens, Crystalline; Lovastatin; Microsomes; Middle Aged; Organ Culture Techniques; Pravastatin; Simvastatin | 1993 |
HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Topics: Animals; Carotid Arteries; Cell Division; Cholesterol; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Lovastatin; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Reference Values; Simvastatin | 1993 |
Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
Topics: Aging; Animals; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lens, Crystalline; Lovastatin; Microsomes, Liver; Organ Culture Techniques; Pravastatin; Rats; Rats, Wistar; Simvastatin; Time Factors | 1993 |
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Drug Eruptions; Epidermis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Skin Diseases, Eczematous | 1993 |
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Topics: Cholesterol; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; RNA, Messenger; Simvastatin; Tumor Cells, Cultured; Up-Regulation | 1993 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.
Topics: Animals; Blood Pressure; Dogs; Enzyme Inhibitors; Female; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Pravastatin; Simvastatin; Time Factors | 1995 |
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Membrane Potentials; Muscle, Skeletal; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1995 |
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Myopathies; Pravastatin; Simvastatin | 1995 |
Cost of lipid-lowering statin drugs.
Topics: Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Microsomes, Liver; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Topics: Animals; Calcium; Cell Differentiation; Cell Division; Cells, Cultured; Cholesterol; Creatine Kinase; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Lovastatin; Mevalonic Acid; Muscle Proteins; Muscle, Skeletal; Phospholipids; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1996 |
Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro.
Topics: Cells, Cultured; Cholesterol; Culture Media; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Granulosa Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Luteinizing Hormone; Pravastatin; Progesterone; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Influence on HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice.
Topics: Animals; Antibody Formation; Enzyme Inhibitors; Female; Hemolytic Plaque Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred BALB C; Pravastatin; Simvastatin | 1995 |
Effects of systemic treatment with statins on skin barrier function and stratum corneum water-holding capacity.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticholesteremic Agents; Cell Membrane Permeability; Epidermis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Water Loss, Insensible | 1996 |
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lovastatin; Microsomes, Liver; Mixed Function Oxygenases; Pravastatin; Simvastatin; Stereoisomerism; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 1996 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Topics: Cyclosporine; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interleukin-2; Killer Cells, Natural; Lovastatin; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes; Mevalonic Acid; Phytohemagglutinins; Pravastatin; Simvastatin; Sterols | 1996 |
Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Circadian Rhythm; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Reproducibility of Results; Simvastatin; Xanthomatosis, Cerebrotendinous | 1996 |
Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.
Topics: Animals; Anticholesteremic Agents; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique, Indirect; Fluvastatin; Image Processing, Computer-Assisted; Indoles; Infusion Pumps, Implantable; Injections, Intraperitoneal; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Simvastatin | 1995 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
HMG-CoA reductase inhibitor treatment in renal insufficiency.
Topics: Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lovastatin; Pravastatin; Rhabdomyolysis; Simvastatin | 1996 |
Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
Topics: Acetic Acid; Adenosine Triphosphate; Anticholesteremic Agents; Cell Division; Cell Survival; Cells, Cultured; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mitochondria; Muscle, Skeletal; Oxidoreductases; Pravastatin; Simvastatin; Sterols | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Fibrinogen; Humans; Lovastatin; Pravastatin; Serotonin; Simvastatin | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Fibrinogen; Humans; Hypercholesterolemia; Lovastatin; Platelet Aggregation; Pravastatin; Simvastatin | 1996 |
[Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
Topics: Bone Marrow Cells; Enzyme Inhibitors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Simvastatin inhibits the division and induces neurite-like outgrowth in PC12 cells.
Topics: Acyl Coenzyme A; Animals; Cell Division; Enzyme Inhibitors; Lovastatin; Mevalonic Acid; Neurites; PC12 Cells; Pravastatin; Rats; Simvastatin | 1996 |
Lipid-lowering for prevention of coronary heart disease: what policy now?
Topics: Adult; Age Factors; Aged; Cholesterol; Coronary Disease; Costs and Cost Analysis; Female; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Risk; Simvastatin; United Kingdom | 1996 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Enzyme Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Myeloid; Lovastatin; Pravastatin; Simvastatin | 1997 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Enzyme Inhibitors; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Morbidity; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin | 1997 |
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Topics: Anticholesteremic Agents; Cell Division; Cells, Cultured; Cholesterol; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; ras Proteins; Simvastatin | 1997 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C3H; Oxidation-Reduction; Pravastatin; Simvastatin | 1997 |
[The mechanism of action of hypolipidemic drugs].
Topics: Adipose Tissue; Anticholesteremic Agents; Cholesterol, LDL; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipase; Lipid Peroxidation; Lipoproteins, VLDL; Liver; Lovastatin; Microbodies; Nuclear Proteins; Pravastatin; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Simvastatin; Transcription Factors | 1997 |
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; Dogs; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipids; Liver; Lovastatin; Male; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Sterols | 1997 |
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
Topics: Cerebrovascular Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Mortality; Pravastatin; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1997 |
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin | 1997 |
"Statin" drugs, mortality, and stroke prevention.
Topics: Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Meta-Analysis as Topic; Mortality; Pravastatin; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin | 1997 |
Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Plasmapheresis; Pravastatin; Regression Analysis; Risk Factors; Simvastatin | 1997 |
Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; Male; Malondialdehyde; Muscle Relaxation; Pravastatin; Rabbits; Simvastatin | 1997 |
[Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells].
Topics: Anilides; Anticholesteremic Agents; Caco-2 Cells; Cholesterol; Cholesterol Esters; Clofibrate; Cyclohexanes; Dioxanes; Esterification; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Phenylurea Compounds; Pravastatin; Probucol; Simvastatin; Sterol O-Acyltransferase | 1997 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
Lipid-lowering therapy in low-risk patients.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Pravastatin; Risk Factors; Simvastatin | 1998 |
HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation.
Topics: Antibodies, Monoclonal; B-Lymphocytes; CD40 Antigens; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Kinetics; Lymphocyte Activation; Mitogens; Palatine Tonsil; Pravastatin; Recombinant Proteins; Simvastatin | 1998 |
Cholesterol drugs revisited.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Humans; Hypercholesterolemia; Pravastatin; Simvastatin | 1998 |
NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery.
Topics: Animals; Aorta; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell Line; DNA; Eukaryotic Cells; Extracellular Matrix; Fibronectins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Quinolines; Rabbits; Simvastatin; Transforming Growth Factor beta; Tunica Intima; Tunica Media | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
Topics: Animals; Cholesterol; Creatine Kinase; Electromyography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Diseases; Myotonia; Necrosis; Phospholipids; Pravastatin; Rabbits; Simvastatin; Tissue Distribution; Ubiquinone | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Natural statins and stroke risk.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin; Simvastatin | 1999 |
The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cohort Studies; Coronary Angiography; Coronary Disease; Data Interpretation, Statistical; Diabetes Complications; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Smoking; Treatment Outcome | 1998 |
Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle.
Topics: Animals; Anticholesteremic Agents; Dose-Response Relationship, Drug; Electric Stimulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Muscle Contraction; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1999 |
The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Clinical Trials as Topic; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; International Normalized Ratio; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin; Time Factors; Warfarin | 1999 |
Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts.
Topics: Animals; Apoptosis; Benzoquinones; Cell Line; Cell Size; DNA Fragmentation; Genistein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactams, Macrocyclic; Mevalonic Acid; Molecular Weight; Muscle, Skeletal; Phosphorylation; Phosphotyrosine; Pravastatin; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Quinones; Rats; Rifabutin; Signal Transduction; Simvastatin; Time Factors | 1999 |
Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Topics: Cardiovascular Diseases; Cluster Analysis; Costs and Cost Analysis; Databases, Factual; Diagnosis-Related Groups; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Medical Audit; Middle Aged; Pravastatin; Product Surveillance, Postmarketing; Registries; Retrospective Studies; Severity of Illness Index; Simvastatin; United States | 1999 |
Statins and PHARMAC.
Topics: Anticholesteremic Agents; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Pravastatin; Publishing; Simvastatin; Treatment Outcome | 1999 |
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Topics: Animals; Arginine; Calcium; Calcium Channel Blockers; Calcium Channels; Cytosol; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Islets of Langerhans; Potassium Chloride; Pravastatin; Rats; Signal Transduction; Simvastatin | 1999 |
Statins and C-reactive protein.
Topics: C-Reactive Protein; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1999 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
The change of cost: reference-based pricing and the statins.
Topics: Anticholesteremic Agents; Canada; Cardiovascular Diseases; Drug Costs; Economics, Pharmaceutical; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Pravastatin; Simvastatin | 1999 |
Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
Topics: Aged; Anticholesteremic Agents; California; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Health Planning; Hospitals, Veterans; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Simvastatin | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Calcium; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Drug Interactions; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1999 |
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Topics: Angiotensin II; Animals; Animals, Newborn; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cell Division; Cell Membrane; Cells, Cultured; DNA; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Myocardium; Naphthalenes; Pravastatin; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; RNA; Simvastatin | 1999 |
Heart lines. Do statins make blood less sticky?
Topics: Blood Coagulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Simvastatin; Thrombin; Thrombosis | 1999 |
The effects of changing statins on cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; New Zealand; Practice Patterns, Physicians'; Pravastatin; Simvastatin; Treatment Outcome | 1999 |
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats.
Topics: Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Bile; Blotting, Western; Cholesterol; Diosgenin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver; Male; Phospholipids; Pravastatin; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 1999 |
Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Organ Size; Pravastatin; Simvastatin; Time Factors; Transaminases; Triglycerides | 1999 |
Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver.
Topics: Animals; Binding, Competitive; Fatty Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Microsomes, Liver; Oxidation-Reduction; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Triglycerides | 1999 |
Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Topics: Cell Division; Cells, Cultured; Collagen; DNA; Extracellular Matrix Proteins; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin; Thrombospondins; Transcription, Genetic; Transforming Growth Factor beta | 1999 |
After 4S, CARE and LIPID--is evidence-based medicine being practised?
Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Humans; Hypercholesterolemia; Pravastatin; Risk Factors; Simvastatin | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2000 |
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Computer Simulation; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Sex Factors; Simvastatin | 2000 |
RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Costs; Economics, Pharmaceutical; Humans; Indoles; New Zealand; Pravastatin; Simvastatin | 1999 |
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
Topics: Animals; Antigens, Nuclear; Aorta; Apoptosis; Cattle; CDC2-CDC28 Kinases; Cell Division; Cell Survival; Cells, Cultured; Coronary Vessels; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Ki-67 Antigen; Lovastatin; Mevalonic Acid; Mice; Mice, Transgenic; Muscle, Smooth, Vascular; Nuclear Proteins; Pravastatin; Protein Serine-Threonine Kinases; Rats; Retinoblastoma Protein; Simvastatin; Tumor Suppressor Protein p53 | 2000 |
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Topics: Administration, Oral; Algorithms; Cholesterol, LDL; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Models, Economic; Pravastatin; Simvastatin; Treatment Outcome | 1999 |
[Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Simvastatin; Survival Rate | 2000 |
Inhibition of monocyte chemotactic protein-1 synthesis by statins.
Topics: Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Lovastatin; Mevalonic Acid; Monocytes; Pravastatin; RNA, Messenger; Simvastatin | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Fas Ligand Protein; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Reference Values; Sensitivity and Specificity; Simvastatin | 2000 |
Inhibitory effect of statins on fetal bovine serum-induced proliferation of rat cultured mesangial cells and correlation between their inhibitory effect and transport characteristics.
Topics: Animals; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glomerular Mesangium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Simvastatin; Temperature | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
[Which statin is more efficient? Concepts and applications in economic evaluation].
Topics: Anticholesteremic Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics.
Topics: Adult; Blood Flow Velocity; Carotid Arteries; Electric Impedance; Femoral Artery; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Pravastatin; Pulse; Retrospective Studies; Simvastatin; Time Factors; Tunica Intima; Tunica Media; Ultrasonography | 2001 |
[Toxic liver damage caused by HMG-CoA reductase inhibitor].
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Pravastatin; Simvastatin | 2000 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Risk Factors; Simvastatin; Stroke | 2001 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Use of the statins in patients after acute myocardial infarction: does evidence change practice?
Topics: Aged; Clinical Trials as Topic; Drug Utilization; Evidence-Based Medicine; Female; Humans; Hypolipidemic Agents; Lipids; Male; Medicine; Myocardial Infarction; Practice Patterns, Physicians'; Pravastatin; Publishing; Simvastatin; Specialization; Survival Rate | 2001 |
[Antioxidative effects of fluvastatin, and its major metabolites [II]].
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Depression, Chemical; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Microsomes, Liver; Pravastatin; Probucol; Simvastatin; Stereoisomerism; Structure-Activity Relationship | 2001 |
Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis.
Topics: Bacteriophages; DNA Damage; DNA, Single-Stranded; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Mutagenesis; Mutagenicity Tests; Oxidative Stress; Pravastatin; Reactive Oxygen Species; Salmonella typhimurium; Simvastatin | 2001 |
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Topics: Anticholesteremic Agents; Cholelithiasis; Double-Blind Method; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pregnancy; Risk Factors; Simvastatin | 2001 |
Is a statin a statin?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 2001 |
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.
Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water | 2001 |
Randomized clinical trials and recent patterns in the use of statins.
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Female; Health Surveys; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; United States | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Topics: Antioxidants; Cell Movement; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lysophosphatidylcholines; Mevalonic Acid; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Oxidative Stress; Phospholipase D; Pravastatin; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein-Tyrosine Kinases; Simvastatin | 2001 |
Simvastatin-associated memory loss.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Male; Memory Disorders; Middle Aged; Pravastatin; Recovery of Function; Simvastatin | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Spectrophotometry, Ultraviolet | 2001 |
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Arachidonic Acid; Cholesterol; Cholesterol, LDL; Diet, Reducing; Fatty Acids; Female; Fenofibrate; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 2001 |
Effect of cholesterol-lowering therapy on endothelial function.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Circulation; Coronary Disease; Endothelium, Vascular; Humans; Hypercholesterolemia; Infusions, Intra-Arterial; Microcirculation; Pravastatin; Simvastatin; Vascular Resistance; Vasomotor System | 2001 |
Statins and dementia.
Topics: Anticholesteremic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Selection Bias; Simvastatin | 2001 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Topics: Actins; Blotting, Northern; Cell Line; Connective Tissue Growth Factor; Cytoskeleton; Dose-Response Relationship, Drug; Gene Expression Regulation; Growth Substances; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lovastatin; Lysophospholipids; Mevalonic Acid; Polyisoprenyl Phosphates; Pravastatin; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; RNA, Messenger; Sesquiterpenes; Simvastatin | 2001 |
The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Cohort Studies; Coronary Disease; Disease-Free Survival; Female; Humans; Male; Pravastatin; Simvastatin; Statistics as Topic | 2001 |
Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species.
Topics: Animals; Antioxidants; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Microsomes, Liver; Oxygen; Pravastatin; Probucol; Rats; Reactive Oxygen Species; Simvastatin; Singlet Oxygen; Vitamin E | 2001 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol.
Topics: Aged; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Risk Factors; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2001 |
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors | 2001 |
Effect of statins on bone mineral density and bone histomorphometry in rodents.
Topics: Animals; Atorvastatin; Bone Density; Bone Development; Bone Resorption; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ovariectomy; Pravastatin; Pyrroles; Radiography; Rats; Rats, Sprague-Dawley; Simvastatin | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prevalence; Simvastatin; Triglycerides | 2002 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Swine | 2002 |
Influence of simvastatin, pravastatin, and BM 15.766 on neutral sterols in liver and testis of guinea pigs.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Gas Chromatography-Mass Spectrometry; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Piperazines; Pravastatin; Simvastatin; Sterols; Testis | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells.
Topics: Acetates; Acetyl Coenzyme A; Carbon Isotopes; Carcinoma, Hepatocellular; Cholesterol; Duodenum; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isotope Labeling; Kinetics; Liver; Liver Neoplasms; Models, Biological; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
Statins and risk of polyneuropathy: a case-control study.
Topics: Aged; Case-Control Studies; Causality; Denmark; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Logistic Models; Lovastatin; Male; Middle Aged; Odds Ratio; Polyneuropathies; Pravastatin; Registries; Risk; Risk Assessment; Simvastatin | 2002 |
Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aorta, Thoracic; Calcium; Collagen Type VIII; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lovastatin; Male; Models, Cardiovascular; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1996 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
Are some statins more equal than others.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2002 |
Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Drug Administration Schedule; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Macaca fascicularis; Male; Matrix Metalloproteinases; Pravastatin; Simvastatin; Thromboplastin; Tunica Intima; Tunica Media; Vascular Cell Adhesion Molecule-1; Vasodilation | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Health Services for the Aged; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; New York; Peripheral Vascular Diseases; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
Topics: Algorithms; Animals; Anticholesteremic Agents; Area Under Curve; Autoradiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Liver; Male; Pravastatin; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Silver Staining; Simvastatin; Sulfonamides; Tissue Distribution | 2002 |
Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Blood Urea Nitrogen; Creatinine; Deoxyguanosine; Diabetes Mellitus, Experimental; DNA; DNA Damage; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney; Liver; Male; Mice; Mice, Inbred ICR; Oxidative Stress; Pravastatin; Simvastatin; Weight Gain | 2002 |
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome | 2002 |
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Topics: Animals; Bone Resorption; Calcium; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Osteoclasts; Osteogenesis; Parathyroidectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin; Thyroidectomy | 2003 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Muscular adverse effects of statins.
Topics: Anticholesteremic Agents; Fatty Acids, Monounsaturated; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2003 |
Statin therapy and small fibre neuropathy: a serial electrophysiological study.
Topics: Anticholesteremic Agents; Electric Stimulation; Electrophysiology; Humans; Hypercholesterolemia; Lower Extremity; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Diseases; Pravastatin; Simvastatin | 2003 |
Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins.
Topics: Aryldialkylphosphatase; Carboxylic Ester Hydrolases; DNA; Esterases; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Gene Expression Regulation, Enzymologic; Humans; Hypolipidemic Agents; Indoles; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Tumor Cells, Cultured | 2003 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
Topics: Drug Industry; Fatty Acids, Monounsaturated; Fees, Pharmaceutical; Fluvastatin; Government Agencies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insurance Coverage; Insurance, Pharmaceutical Services; National Health Programs; New Zealand; Politics; Pravastatin; Rate Setting and Review; Simvastatin | 2003 |
[Statin treatment in type 2 diabetes. Is it a must today?].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Life Style; Middle Aged; Placebos; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Topics: Coronary Disease; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Simvastatin | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.
Topics: Animals; Anticholesteremic Agents; Basilar Artery; Calcium Channel Blockers; Calcium Channels, L-Type; Female; In Vitro Techniques; Lovastatin; Mevalonic Acid; Muscle Relaxation; Muscle, Smooth, Vascular; Patch-Clamp Techniques; Pilot Projects; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density.
Topics: Absorptiometry, Photon; Bone Density; Bone Remodeling; Estrogen Replacement Therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Osteoporosis, Postmenopausal; Pravastatin; Retrospective Studies; Simvastatin | 2003 |
Current perspectives on statins.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Artery Disease; Female; Humans; India; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Effects of statins on adhesion molecule expression in endothelial cells.
Topics: Cell Adhesion Molecules; E-Selectin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Flow Cytometry; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Saphenous Vein; Simvastatin; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2003 |
Differential effects of lipid-lowering agents on human cholinesterases.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Dementia; Humans; Hypolipidemic Agents; Lovastatin; Molecular Structure; Pravastatin; Simvastatin | 2004 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Aorta, Thoracic; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fetal Blood; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Pravastatin; Probucol; Pyridines; Rabbits; Simvastatin; Swine; Xanthine; Xanthine Oxidase | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Statins induce the regression of left ventricular mass in patients with angina.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cardiomegaly; Case-Control Studies; Constriction, Pathologic; Drug Evaluation; Female; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 2004 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter.
Topics: Adult; Animals; Apolipoproteins B; Humans; Lipoproteins, LDL; Male; Metabolic Clearance Rate; Mice; Mice, Transgenic; Middle Aged; Models, Animal; Particle Size; Pravastatin; Regression Analysis; Simvastatin | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Blood Coagulation Factors; Case-Control Studies; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pravastatin; Risk; Simvastatin; Venous Thrombosis | 2004 |
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Topics: Adult; Annexin A5; Apoptosis; Atorvastatin; Caspase 3; Caspases; Cholesterol; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.
Topics: Animals; Brain; Cell Line; Cholesterol; Cholesterol 24-Hydroxylase; Guinea Pigs; Humans; Hydroxycholesterols; Male; Pravastatin; Simvastatin; Steroid Hydroxylases; Sterols; Transfection | 2004 |
Updated guidelines support even lower cholesterol levels for at-risk patients.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States | 2004 |
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
Topics: Cells, Cultured; Endocytosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Receptors, Cell Surface; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex.
Topics: Animals; Blood-Brain Barrier; Brain Chemistry; Cell Division; Cerebral Cortex; Cholesterol; Chromatography, Liquid; Female; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mice; Mice, Inbred C57BL; Neural Pathways; Oligonucleotide Array Sequence Analysis; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Simvastatin | 2005 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Glomerulus; Male; Myocardium; Myocytes, Cardiac; Pravastatin; Rats; Rats, Inbred SHR; Simvastatin; Triglycerides; Ventricular Remodeling | 2005 |
Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease.
Topics: Animals; Aortic Valve; Calcinosis; Cell Differentiation; Cells, Cultured; Cholesterol; Fibroblasts; Heart Valve Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Pravastatin; Protein Prenylation; Simvastatin; Stromal Cells; Swine | 2005 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Effects of statins on vascular function of endothelin-1.
Topics: Animals; Aorta; Cells, Cultured; Dogs; Endothelin-1; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Nucleic Acid Synthesis Inhibitors; Pravastatin; Rats; Rats, Sprague-Dawley; rho GTP-Binding Proteins; Simvastatin; Vasoconstriction | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Topics: Aged; Antioxidants; Cholestenes; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Indoles; Male; Middle Aged; Oxidative Stress; Pravastatin; Prospective Studies; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist.
Topics: Anticholesteremic Agents; C-Reactive Protein; Down-Regulation; Gene Expression Regulation; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1; Interleukin-6; Nitric Oxide; Pravastatin; RNA, Messenger; Simvastatin; STAT3 Transcription Factor; Tumor Cells, Cultured | 2006 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States | 2005 |
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages.
Topics: Animals; Atorvastatin; Cell Proliferation; Concanavalin A; Heptanoic Acids; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microspheres; Mitogens; Phagocytosis; Pravastatin; Pyrroles; Simvastatin; Spleen | 2006 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
Topics: Animals; Brain; Cholesterol; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Mice; Phytosterols; Pravastatin; Simvastatin | 2006 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Japan; Lymphoma; Male; Multiple Myeloma; Pravastatin; Risk Factors; Simvastatin | 2006 |
Statin wars following coronary revascularization--evidence-based clinical practice?
Topics: Aged; Drug Prescriptions; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Ischemia; Myocardial Revascularization; Outpatients; Postoperative Care; Pravastatin; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
A switch in time saves more than nine. Two popular statins, Pravachol and Zocor, go generic this summer, paving the way for significant savings.
Topics: Anticholesteremic Agents; Drugs, Generic; Humans; Insurance, Pharmaceutical Services; Patents as Topic; Pravastatin; Prescription Fees; Simvastatin | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.
Topics: Atorvastatin; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Organ Failure; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Survival Rate | 2006 |
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
[For coronary disease patients is certain: the lower the LDL the better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Fatty Acids, Monounsaturated; Fluvastatin; G1 Phase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; p21-Activated Kinases; Phosphorylation; Pravastatin; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Simvastatin | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
The MEGA study.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis.
Topics: Cell Line; Cytoplasmic Granules; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Exocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Granzymes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Killer Cells, Natural; Lysosomal-Associated Membrane Protein 1; Mevalonic Acid; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2007 |
Preservation of the blood brain barrier integrity may underlie neuroprotective effects of statins in Alzheimer's disease.
Topics: Alzheimer Disease; Blood-Brain Barrier; Brain; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Neuroprotective Agents; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2006 |
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Topics: Animals; Anticholesteremic Agents; Biological Transport; Cell Line; CHO Cells; Chromans; Cricetinae; Cricetulus; Drug Interactions; Estrone; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Protein Binding; Recombinant Proteins; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Taurocholic Acid; Thiazolidinediones; Troglitazone | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; NF-kappa B; Nicotine; Nicotinic Agonists; Pravastatin; Protein Kinase C; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Smoking; Superoxide Dismutase; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromans; Dose-Response Relationship, Drug; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mammary Neoplasms, Animal; MAP Kinase Kinase 4; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Simvastatin; Vitamin E | 2007 |
Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Amides; Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Mevalonic Acid; Mice; Monomeric GTP-Binding Proteins; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Pravastatin; Pyridines; rho-Associated Kinases; Simvastatin; Tumor Necrosis Factor-alpha | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Topics: Anabolic Agents; Animals; Animals, Newborn; Bone and Bones; Bone Resorption; Cells, Cultured; Disease Models, Animal; Female; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred BALB C; Osteoclasts; Osteoporosis; Ovariectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; rap1 GTP-Binding Proteins; Signal Transduction; Simvastatin; Water | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Patient Selection; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Sex Factors; Simvastatin; Tablets | 2007 |
Regulation of the PTEN promoter by statins and SREBP.
Topics: Cell Line; Electrophoretic Mobility Shift Assay; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; PPAR gamma; Pravastatin; Promoter Regions, Genetic; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Up-Regulation | 2008 |
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
The association between statins and cancer incidence in a veterans population.
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans | 2008 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Case-Control Studies; Cell Adhesion; Cell Adhesion Molecules; Coronary Artery Disease; Endothelial Cells; Endothelium, Vascular; Female; Homocysteine; Humans; Male; Middle Aged; Pravastatin; Simvastatin | 2008 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
'Real-life' reduction in cholesterol with statins, 1993 to 2002.
Topics: Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Patient Compliance; Pravastatin; Scotland; Simvastatin; Treatment Outcome | 2008 |
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship | 2008 |
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Longitudinal Studies; Male; Middle Aged; Pravastatin; Pyridines; Retrospective Studies; Scotland; Simvastatin; Treatment Outcome | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Apoptosis; Barrett Esophagus; Caspase 3; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lovastatin; Mevalonic Acid; Nitrobenzenes; Polyisoprenyl Phosphates; Pravastatin; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Simvastatin; Sulfonamides | 2008 |
Statins in esophageal cancer cell lines: promising lead?
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Can cheap generic statins achieve national cholesterol lowering targets?
Topics: Anticholesteremic Agents; Drugs, Generic; England; Goals; Hospitals, Public; Humans; Hypercholesterolemia; Outcome Assessment, Health Care; Pravastatin; Quality Indicators, Health Care; Simvastatin | 2008 |
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.
Topics: Aged; Bayes Theorem; C-Reactive Protein; Female; Hepatocyte Nuclear Factor 1-alpha; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Simvastatin | 2008 |
Re: The association between statins and cancer incidence in a veterans population.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression.
Topics: Acyl Coenzyme A; Amides; Anticholesteremic Agents; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Kidney; Leucine; Lipopolysaccharides; NF-kappa B; Pravastatin; Pyridines; Signal Transduction; Simvastatin; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?
Topics: Atorvastatin; Cells, Cultured; Chemotactic Factors; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Infiltration; Neutrophils; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; rhoA GTP-Binding Protein; Simvastatin | 2009 |
Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model.
Topics: Animals; Cytochrome P-450 CYP3A; Female; Glucocorticoids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Liver; Methylprednisolone; Osteonecrosis; Pravastatin; Probucol; Rabbits; Simvastatin | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats.
Topics: Amides; Androstadienes; Animals; Caspase 3; Cell Culture Techniques; Cell Survival; Creatine Kinase; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fibroblasts; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Infusions, Intravenous; L Cells; Mice; Muscle, Skeletal; Pravastatin; Pyridines; Rats; rho-Associated Kinases; rhoA GTP-Binding Protein; Simvastatin; Subcellular Fractions; Time Factors; Wortmannin | 2009 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rhabdomyolysis; Risk Assessment; Risk Factors; Simvastatin; Young Adult | 2009 |
Preoperative statin use and infection after cardiac surgery: a cohort study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemoprevention; Cohort Studies; Female; Heptanoic Acids; Hospitals, University; Humans; Immunologic Factors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Surgical Wound Infection; Thoracic Surgery; Treatment Outcome | 2009 |
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Topics: Cardiovascular Diseases; Cell Line; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Serum Albumin; Simvastatin | 2009 |
Re: Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Regeneration; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Rabbits; Simvastatin | 2009 |
Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelium; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Signal Transduction; Simvastatin; Uterine Cervical Neoplasms; Water | 2010 |
Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells.
Topics: Alzheimer Disease; Apolipoproteins E; Astrocytes; ATP-Binding Cassette Transporters; Blotting, Western; Cells, Cultured; Electrophoresis; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Phospholipid Transfer Proteins; Polymerase Chain Reaction; Pravastatin; Simvastatin; tau Proteins | 2009 |
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice.
Topics: Abortion, Habitual; Animals; Antibodies, Antiphospholipid; Female; Injections, Intraperitoneal; Mice; Mice, Knockout; Mice, Transgenic; Neutrophil Activation; Neutrophils; Pravastatin; Pregnancy; Receptor, PAR-2; Simvastatin; Thromboplastin | 2009 |
Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Adhesion; Cell Shape; Cell Survival; Dose-Response Relationship, Drug; Eosinophils; Fatty Acids, Monounsaturated; Fluvastatin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Lovastatin; Macrophage-1 Antigen; Mevalonic Acid; Microfluidic Analytical Techniques; Microfluidics; Pravastatin; Recombinant Proteins; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Variation; Genotype; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Metabolic Clearance Rate; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pravastatin; Simvastatin | 2009 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; Dopamine; Humans; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroglia; Neurons; Neuroprotective Agents; Neurotransmitter Agents; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Pravastatin; Proto-Oncogene Proteins p21(ras); Simvastatin; Substantia Nigra | 2009 |
Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Topics: Cardiovascular Diseases; Drug Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome and Process Assessment, Health Care; Pravastatin; Secondary Prevention; Simvastatin; Stroke | 2010 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosis.
Topics: Animals; Antigens, Differentiation; Atherosclerosis; Cell Line; Disease Models, Animal; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Fatty Acids; Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Phosphorylation; Pravastatin; Receptors, LDL; Regulatory Factor X Transcription Factors; Simvastatin; Stress, Physiological; Transcription Factors | 2010 |
Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.
Topics: Amides; Animals; Bleomycin; Connective Tissue Growth Factor; Cytoskeleton; Endomyocardial Fibrosis; Female; Heart; Lung; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Pravastatin; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Radiation Injuries; Radiation Pneumonitis; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; rho-Associated Kinases; rhoB GTP-Binding Protein; Simvastatin; Smad Proteins; Thorax | 2010 |
Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78.
Topics: Actins; Acyl Coenzyme A; Animals; Cell Division; Endoplasmic Reticulum Chaperone BiP; Glomerular Mesangium; Glucose; Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Lovastatin; Mice; Pravastatin; Simvastatin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetradecanoylphorbol Acetate | 2010 |
On the combined effect of statins and lycopene on cytokine production by human peripheral blood cells.
Topics: Anti-Inflammatory Agents; Carotenoids; Cells, Cultured; Cytokines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukin 1 Receptor Antagonist Protein; Interleukin-10; Interleukin-1beta; Interleukin-2; Leukocytes, Mononuclear; Lycopene; Pravastatin; Simvastatin; Tumor Necrosis Factor-alpha | 2010 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2010 |
Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Duodenum; Garlic; Gene Expression Regulation; Humans; Liver; Male; Plant Extracts; Pravastatin; Saquinavir; Simvastatin | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Statins have an early antiplatelet effect in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Pravastatin; Simvastatin | 2011 |
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand | 2011 |
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pravastatin; Pyrroles; Simvastatin; Tetradecanoylphorbol Acetate; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Statins promote the growth of experimentally induced cerebral aneurysms in estrogen-deficient rats.
Topics: Animals; Apoptosis; Brain; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Estrogens; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 2011 |
The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuroprotective Agents; Pravastatin; Rats; Rats, Wistar; Simvastatin; Streptozocin | 2011 |
HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jurkat Cells; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Phagocytosis; Pravastatin; Pyrimidines; RNA Interference; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Transfection; Up-Regulation | 2011 |
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.
Topics: Apoptosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Genetic Pleiotropy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pulmonary Artery; Pyrroles; Simvastatin | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
Topics: Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Fluorescence; Neoplasms; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Tandem Mass Spectrometry | 2011 |
HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model.
Topics: Animals; Cicatrix, Hypertrophic; Disease Models, Animal; Ear; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Simvastatin; Wound Healing | 2012 |
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2012 |
Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Hypercholesterolemia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Rabbits; Simvastatin | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Development and validation of a simple and fast HPLC method for determination of lovastatin, pravastatin and simvastatin.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lovastatin; Naphthalenes; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Simvastatin | 2012 |
Selected statins produce rapid spinal motor neuron loss in vitro.
Topics: Animals; Biomarkers; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Motor Neurons; Neurites; Pravastatin; Rats; Schwann Cells; Simvastatin; Spinal Nerves; Time Factors; Tissue Culture Techniques | 2012 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
Topics: Animals; Atorvastatin; Calcium; Cell Line; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Mice; Microglia; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Signal Transduction; Simvastatin; Up-Regulation | 2012 |
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30 | 2012 |
The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test.
Topics: Analgesics; Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Naloxone; NG-Nitroarginine Methyl Ester; Pravastatin; Pyrroles; Simvastatin | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Can statins reduce the inflammatory response associated with preterm birth in an animal model?
Topics: Animals; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Pravastatin; Pregnancy; Premature Birth; Simvastatin | 2012 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Effects of statins and cholesterol on memory functions in mice.
Topics: Acetylcholinesterase; Algorithms; Animals; Avoidance Learning; Brain Chemistry; Cholesterol; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Memory; Mice; Mice, Inbred C57BL; Pravastatin; Simvastatin; Transfer, Psychology | 2012 |
RHOA is a modulator of the cholesterol-lowering effects of statin.
Topics: Alleles; Biomarkers, Pharmacological; Cell Line, Transformed; Cholesterol; Clinical Trials as Topic; Gene Expression; Humans; Lipid Metabolism; Polymorphism, Single Nucleotide; Pravastatin; rhoA GTP-Binding Protein; RNA, Messenger; Simvastatin | 2012 |
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase | 2013 |
New statins also produce fatigue: spontaneous reporting as a complementary system to increase safety knowledge.
Topics: Cholesterol, LDL; Exercise Test; Fatigue; Female; Humans; Male; Physical Exertion; Pravastatin; Simvastatin | 2013 |
New statins also produce fatigue: spontaneous reporting as a complementary system to increase safety knowledge--reply.
Topics: Cholesterol, LDL; Exercise Test; Fatigue; Female; Humans; Male; Physical Exertion; Pravastatin; Simvastatin | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Azetidines; Diabetes Mellitus; Drug Interactions; Ezetimibe; Glucose Transporter Type 4; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Simvastatin; Ubiquinone | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
Evaluation of a method using high performance liquid chromatography with ultraviolet detection for the determination of statins in macromycetes of the genus Pleurotus cultivated by fermentation processes.
Topics: Agriculture; Chromatography, High Pressure Liquid; Drug Stability; Fermentation; Limit of Detection; Lovastatin; Pleurotus; Pravastatin; Simvastatin; Waste Products | 2013 |
Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth.
Topics: Animals; Antibodies, Neutralizing; Cells, Cultured; Cerebral Cortex; Complement Activation; Complement C5a; Female; Fetus; Gene Expression Regulation; Glutamic Acid; Humans; Infant, Newborn; Mice; Models, Animal; Neurons; Pravastatin; Pregnancy; Premature Birth; Receptor, Anaphylatoxin C5a; Receptors, Glutamate; Signal Transduction; Simvastatin | 2014 |
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Biological Availability; Heptanoic Acids; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pravastatin; Pyrroles; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Tissue Distribution; Young Adult | 2014 |
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cells, Cultured; Chemokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Inflammation Mediators; Leukocytes, Mononuclear; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2014 |
Anti-inflammatory effects of hydrophilic and lipophilic statins with hyaluronic acid against LPS-induced inflammation in porcine articular chondrocytes.
Topics: Animals; Chondrocytes; Collagen Type II; Hyaluronic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Injections, Intra-Articular; Lipopolysaccharides; NF-kappa B p50 Subunit; Nitric Oxide Synthase Type II; Osteoarthritis; Pravastatin; Real-Time Polymerase Chain Reaction; Simvastatin; Swine; Viscosupplements | 2014 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma, Experimental; Mice; Necrosis; Oxidation-Reduction; Oxidative Stress; Pravastatin; Simvastatin | 2014 |
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Topics: Animals; Anthelmintics; Apoptosis; Drug Evaluation, Preclinical; Female; Gene Knockdown Techniques; Helminth Proteins; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Male; Mevalonic Acid; Mice; Molecular Targeted Therapy; Pravastatin; RNA Interference; Schistosoma mansoni; Schistosomiasis mansoni; Simvastatin | 2014 |
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Socioeconomic Factors | 2014 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes.
Topics: Animals; Cell Membrane; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kv1.3 Potassium Channel; Lovastatin; Male; Mice, Inbred Strains; Pravastatin; Simvastatin; Thymocytes | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells.
Topics: Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Survival; Drug Synergism; Furans; Hippurates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indican; Indoleacetic Acids; Pravastatin; Propionates; Rhabdomyosarcoma; Simvastatin; Toxins, Biological; Uremia | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Attenuation of acetylcholine activated potassium current (I KACh) by simvastatin, not pravastatin in mouse atrial cardiomyocyte: possible atrial fibrillation preventing effects of statin.
Topics: Acetylcholine; Action Potentials; Animals; Atrial Fibrillation; Electrophysiological Phenomena; Heart Atria; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Myocytes, Cardiac; Potassium; Pravastatin; Simvastatin | 2014 |
Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Risk Assessment; Simvastatin | 2015 |
The effect of simvastatin and pravastatin on arterial blood pressure, baroreflex, vasoconstrictor, and hypertensive effects of angiotensin II in Sprague-Dawley rats.
Topics: Angiotensin II; Animals; Baroreflex; Blood Pressure; Drug Synergism; Heart Rate; Hypertension; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstriction | 2014 |
Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Membrane Proteins; Mesenchymal Stem Cells; Mevalonic Acid; NF-kappa B; Pravastatin; Proto-Oncogene Proteins; Signal Transduction; Simvastatin; Time Factors; Transcription Factor RelA | 2015 |
Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells.
Topics: Animals; Bacterial Proteins; Bacterial Toxins; Cell Line, Transformed; Epithelial Cells; Hemolysin Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Innate; Injections, Intraperitoneal; Lung; Mice; Mice, Inbred C57BL; Pravastatin; Primary Cell Culture; Respiratory Mucosa; Simvastatin; Staphylococcus aureus; Streptococcus pneumoniae; Streptolysins | 2015 |
Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin.
Topics: Area Under Curve; Drug Monitoring; Feasibility Studies; Female; Humans; Male; Pravastatin; Regression Analysis; Reproducibility of Results; Simvastatin | 2016 |
Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Bacterial Adhesion; Biofilms; Drug Repositioning; Enterococcus faecalis; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Pravastatin; Pseudomonas aeruginosa; Simvastatin; Vancomycin | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.
Topics: Adult; Aged; Apolipoprotein C-III; Atorvastatin; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells.
Topics: Adenosine Triphosphate; Animals; Calcium; Cell Line; Colforsin; Cyclic AMP; Diabetes Mellitus; Erythrocyte Membrane; Fatty Acids; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Male; Metabolic Syndrome; Mice; Middle Aged; Pancreas; Pravastatin; Receptors, G-Protein-Coupled; Risk Factors; Signal Transduction; Simvastatin | 2015 |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden | 2016 |
The role of acid-base imbalance in statin-induced myotoxicity.
Topics: Acid-Base Imbalance; Animals; Cell Death; Cell Differentiation; Cell Line; Cell Membrane Permeability; Chromatography, High Pressure Liquid; Culture Media; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Membrane Transport Proteins; Mice; Microsomes, Liver; Muscle Development; Muscles; Plasma; Pravastatin; Simvastatin; Time Factors | 2016 |
Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin.
Topics: Area Under Curve; Atorvastatin; Drug Design; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Linear Models; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2016 |
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
Topics: Endoglin; Female; Heme Oxygenase-1; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Rosuvastatin Calcium; Simvastatin; Trophoblasts; Up-Regulation; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study.
Topics: Aged; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Electronic Health Records; Female; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Software; Tertiary Care Centers; Warfarin | 2016 |
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Topics: Aged; Aged, 80 and over; Atorvastatin; Clinical Trials as Topic; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Interrupted Time Series Analysis; Lovastatin; Male; Nova Scotia; Pravastatin; Prescription Drugs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2016 |
Characterization of interactions of simvastatin, pravastatin, fluvastatin, and pitavastatin with bovine serum albumin: multiple spectroscopic and molecular docking.
Topics: Animals; Binding Sites; Cattle; Fatty Acids, Monounsaturated; Fluvastatin; Hydrogen Bonding; Indoles; Kinetics; Molecular Docking Simulation; Pravastatin; Protein Binding; Quinolines; Serum Albumin, Bovine; Simvastatin; Solutions; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Thermodynamics | 2017 |
A method to estimate the mean lifetime survival increase of statin therapy.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Life Expectancy; Longevity; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; Time Factors | 2016 |
Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
Topics: Age Factors; Body Mass Index; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypertension; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Myalgia; Odds Ratio; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2016 |
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation.
Topics: Animals; Cell Line; Cholesterol; Glucose; Glucose Transporter Type 4; Glycogen; Glycogen Synthase Kinase 3 beta; Insulin; Insulin Resistance; Muscle Fibers, Skeletal; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Simvastatin | 2016 |
Interaction of different statins with model membranes by NMR data.
Topics: Deuterium Oxide; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Magnetic Resonance Spectroscopy; Micelles; Phosphorylcholine; Pravastatin; Simvastatin | 2017 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
Topics: Acidosis; Adult; Animals; Cell Line; Chylomicron Remnants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Mice; Models, Biological; Muscular Diseases; Pravastatin; Simvastatin | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Statin and Its Association With Delirium in the Medical ICU.
Topics: Aged; Atorvastatin; Delirium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Male; Middle Aged; Odds Ratio; Pravastatin; Propensity Score; Reproducibility of Results; Retrospective Studies; Simvastatin | 2017 |
Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.
Topics: Animals; Humans; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Pravastatin; Scrapie; Simvastatin | 2017 |
Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of Statins.
Topics: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolome; Pravastatin; Simvastatin | 2017 |
Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms.
Topics: Animals; Autophagy; Biosynthetic Pathways; Cell Cycle; Cell Death; Cell Differentiation; Cell Survival; Cells, Cultured; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mouse Embryonic Stem Cells; Neural Stem Cells; Polyisoprenyl Phosphates; Pravastatin; RNA, Messenger; Sesquiterpenes; Simvastatin; Sterol Regulatory Element Binding Protein 2; Transcriptome | 2018 |
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Topics: Adult; Aged; Atorvastatin; Depression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Propensity Score; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Suicide, Attempted; United States | 2018 |
Clinical Inquiries. Do statins alter the risk or progression of dementia?
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dementia; Disease Progression; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; United States; United States Food and Drug Administration | 2018 |
Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amides; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cyclohexenes; Cytokines; Diphosphonates; Fibroblasts; Fluvastatin; Gene Expression Regulation; Heart; Heart Diseases; Humans; Interleukin-33; Lovastatin; Mevalonic Acid; Monoterpenes; Myocardium; Myocytes, Cardiac; Pravastatin; Pyridines; rhoA GTP-Binding Protein; Simvastatin; Thiazolidines | 2018 |
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Risk Assessment; Rosuvastatin Calcium; Sex Factors; Simvastatin | 2019 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells.
Topics: Atorvastatin; Cell Line; Cell Movement; Cell Proliferation; Endometriosis; Endometrium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Stromal Cells | 2019 |
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Topics: Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lovastatin; Magnetic Resonance Spectroscopy; Phosphatidylcholines; Phospholipids; Pravastatin; Simvastatin | 2019 |
Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation; Humans; Pravastatin; Simvastatin | 2018 |
Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Protective Factors; Rectal Neoplasms; Retrospective Studies; Simvastatin; Survival Rate; Sweden | 2019 |
Association Between Statin Use and Sex Hormone in the Multi-Ethnic Study of Atherosclerosis Cohort.
Topics: Aged; Aged, 80 and over; Asian; Atorvastatin; Black or African American; Case-Control Studies; Dehydroepiandrosterone; Estradiol; Female; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Multivariate Analysis; Pravastatin; Sex Hormone-Binding Globulin; Simvastatin; Testosterone; United States; White People | 2019 |
Pravastatin and Simvastatin Pretreatment in Combination with Pyrimethamine and Sulfadiazine Reduces Infection Process of Toxoplasma gondii Tachyzoites (RH Strain) in HeLa Cells.
Topics: Antiprotozoal Agents; Cell Survival; Drug Synergism; HeLa Cells; Humans; Life Cycle Stages; Pravastatin; Pyrimethamine; Simvastatin; Sulfadiazine; Toxoplasma; Toxoplasmosis | 2019 |
Combined Treatment with Hydrophilic and Lipophilic Statins Improves Neurological Outcomes Following Experimental Cardiac Arrest in Mice.
Topics: Animals; Behavior, Animal; Blood Gas Analysis; Brain Edema; Brain Ischemia; CA1 Region, Hippocampal; Cardiopulmonary Resuscitation; Cytokines; Heart Arrest; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Neuroprotective Agents; Pravastatin; Random Allocation; Simvastatin; Survival Rate | 2020 |
Statins with different lipophilic indices exert distinct effects on skeletal, cardiac and vascular smooth muscle.
Topics: Animals; Female; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microelectrodes; Muscle Contraction; Muscle, Skeletal; Muscle, Smooth, Vascular; Myocardium; Pravastatin; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Transcriptome; Ventricular Function, Left | 2020 |
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
Topics: Animals; Atorvastatin; Caspase 3; Caspase 7; Cell Line; Cell Survival; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Myoblasts; Pravastatin; Protective Agents; Rats; Resveratrol; Signal Transduction; Simvastatin | 2020 |
Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction.
Topics: Cell Survival; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Female; Human Umbilical Vein Endothelial Cells; Humans; Pravastatin; Pre-Eclampsia; Pregnancy; Rosuvastatin Calcium; Simvastatin; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor Receptor-1 | 2020 |
Liposome-encapsulated statins reduce hypertrophic scarring through topical application.
Topics: Animals; Cicatrix, Hypertrophic; Collagen Type I; Collagen Type III; Connective Tissue Growth Factor; Ear, External; Erythema; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liposomes; Melanins; Platelet Endothelial Cell Adhesion Molecule-1; Pravastatin; Rabbits; Simvastatin; Skin; Spectrophotometry | 2020 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
Assessing the Interactions of Statins with Human Adenylate Kinase Isoenzyme 1: Fluorescence and Enzyme Kinetic Studies.
Topics: Adenylate Kinase; Amino Acid Sequence; Atorvastatin; Circular Dichroism; Fluvastatin; Geobacillus stearothermophilus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Isoenzymes; Kinetics; Ligands; Molecular Docking Simulation; Pravastatin; Protein Binding; Recombinant Proteins; Rosuvastatin Calcium; Sequence Alignment; Simvastatin; Spectrometry, Fluorescence; Spectrophotometry; Static Electricity; Temperature | 2021 |
Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.
Topics: Aged; Atorvastatin; Cross-Sectional Studies; Diabetes Mellitus; Glucose; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Prediabetic State; Rosuvastatin Calcium; Simvastatin; Spain | 2022 |
Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2023 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Protein Isoforms; Rosuvastatin Calcium; Simvastatin | 2023 |
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP2C9; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Pharmacogenetics; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2023 |
Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol.
Topics: alpha-Synuclein; Animals; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pravastatin; Protein Aggregates; Simvastatin | 2023 |